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ABSTRACT 
 
Zika virus is a re-emerging infectious disease, which was declared to be a public health 
emergency of international concern due to its various reported complications ranging from 
microcephaly in newborn to Guillain-Barré Syndrome (GBS). Because less attention has been 
paid to this virus over time, literature has been lacking regarding the structural and 
conformational features of its proteins particularly the NS3 helicase protein. This dissertation 
has addressed two major aspects of Zika NS3 helicase protein: (i) the binding interactions and 
(ii) structural dynamics and conformational changes of the protein. 
Investigations were carried out on the various Zika NS3 helicase ligand binding landscapes 
using 10 ligands via molecular docking, of which the best 3 were subjected to molecular 
dynamic simulations and several post dynamics analyses. Ivermectin, HMC-HO1α and lapachol 
emerged as the best 3 ligands. The result of the analysis showed that the binding of Ivermectin 
to ssRNA site and Lapachol and HMC-HO1α to the ATPase site induces a more compact 
protein structure, thus stabilizing residue fluctuations.  The pharmacophoric characteristics 
found in Lapachol, HMC-HO1α and Ivermectin may be utilized in the design of a potent hybrid 
drug that can show efficient inhibition of a multitude of diseases including the detrimental co-
infection of ZIKV, Dengue and Chikungunya. 
Also in this study, a detailed structural dynamic analysis was carried out on the structural 
flexibility of the NS3 helicase protein after NITD008 binding via molecular dynamics 
simulation and other posts dynamic analysis including the Principal Component Analysis (PCA) 
and the Dynamic Cross Correlation (DCC) analysis. Result revealed a prominent shift in the P-
Loop found at the ATP site of the helicase.  This loop and helical flexible regions give new 
insight into the dynamic structural features of ZIKV NS3 Helicase. The PCA and DCC analysis 
result revealed a significant structural flexibility of the NITD008-NS3 Helicase system 
compared to the rigid unbound form of the protein. Furthermore, the NITD008-NS3 Helicase 
complex stability was also ensured via a 130ns molecular dynamic simulation, this has proven 
NITD008 as an effective potential inhibitor of the NS3 helicase protein. This research is of 
immense importance to the discovery of a potent Zika inhibitor and in medicine as it has proven 
potential inhibitors with a good binding affinity towards Zika NS3 helicase. Also, this study 
hopes to fill in the gap of information that has been missing regarding molecular studies on Zika 
virus to some extent.  
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 CHAPTER 1 
 
1.1 Background and rationale of the study 
This chapter outlines the background and novelty of this research project. It then presents the 
Aims and Objectives of the study and concluded by outlining the structure of the following five 
chapters, specifically indicating in which ones the Objectives were addressed. 
The Zika Virus (ZIKV) gained international notoriety shortly before the 2016 Olympics, when 
Brazil was infested with the mosquitoe-borne Zika virus. Concerns were raised about the grave 
consequences of those visiting the epidemic area, specifically pregnant women, due to the 
resulting microcephaly of newly born children and the Gullian barre Syndrome.  Following this 
situation, the World Health Organization declared Zika virus outbreak to be a public emergency 
of international concern on the 1st of February 2016
1
.  Approximately1.5million cases of the 
virus were reported in Brazil during the 2015 outbreak
2
. This was preceded by major outbreaks 
in Micronesia in 2007 and French Polynesia in 2013
3
. The virus has spread rapidly to new 
geographic areas including South and Central America and the potential of this virus to spread 
across the world and affect the lives of millions of people highlight the need to find a cure to 
Zika virus. 
ZIKV belongs to the genus flavivirus and family flaviviridae
4,5
, with other viruses of public 
health concern being Dengue Virus (DENV), West Nile (WNV), Yellow Fever Virus (YFV), 
Japenese Encephalitis Virus (JEV) and Chikungunya Virus (CHIKV)
4,6
. Antiviral agents against 
other flaviviral disease, such as Yellow Fever Virus (YFV), have been discovered, indicating 
the potential to develop an inhibitor to the Zika virus 
7
. ZIKV genome cleaves onto the three 
structural and seven non-structural proteins, of which NS3 helicase is one of the non-structural 
forms
8
. These proteins play a vital role in the lifecycle and replication of the virus, thus forming 
an important target in the design of an inhibitor. The virus shares similar replication schemes 
and genome organizations with other flaviviruses
9
. Its NS3 helicase protein is the second largest 
viral protein and plays an essential role in the viral life cycle. In addition, it has a N-terminal 
protease and a C-terminal domain, both of which have RNA helicase, nucleoside and RNA 
triphosphatase activities that are involved in viral replication and RNA synthesis
10
. These 
multiple activities and the roles it plays in viral replication makes it an attractive target for 
designing a ZIKV inhibitor. Although numerous studies have reported the need for ZIKV drug 
discovery, neither FDA approved drugs nor vaccines are currently available. There is therefore 
the need to design new drug inhibitors that can destroy the virus, with a deeper understanding of 
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2 
the structural, binding and conformational features of the proteins being necessary for this to 
occur. As there is a lack of literature in this regard, designing effective small drug molecule 
inhibitors may be challenging. 
Ligand-protein binding is an important aspect in the field of molecular modeling and drug 
design that gives an insight into the suitability of the binding of a potential inhibitor (ligand) to 
a receptor. Molecular docking, a lock and key technique that fit in a 3dimensional structure of a 
ligand into the active site of the receptor can achieve this. The binding is associated with some 
energy functions (free binding energy) that estimates the degree of the binding and ensures the 
stability of the complex
11
. In addition, the binding is also associated with some interactions 
between the ligand and protein residues via some intermolecular forces.  Upon ligand-protein 
binding, structural changes are usually observed in the protein which changes the conformation 
of the complex
12
. The protein dynamics is an important aspect that need to be monitored 
because the higher the degree of structural change the lesser the docking accuracy
13
. This is a 
challenge that can be resolved via Molecular dynamic (MD) simulation.  
MD simulation is a valuable tool for understanding complex, dynamic phenomena that occur in 
biological systems. This includes conformational changes, protein stability, molecular 
recognition of proteins and complexes, and protein folding, which are very useful in drug design 
and structure determination. The simulation is a computational method that calculates the time 
dependent behavior of a molecular system and provides detailed information on its 
conformational changes and fluctuations. It also examines the dynamics, structure, and 
thermodynamics of the biological systems and their complexes
14
. MD simulation is also 
important in drug design due to its predicting of protein-ligand docking, in which a drug is 
modeled to target a specific site of the protein. The docked protein-ligand is usually rigid with 
poor flexibility, while the MD simulation allows for a proper degree of flexibility of the protein-
ligand complex, thereby giving a better and more stable conformation 
15
. 
1.2 Aim and objectives 
This study has 2 major Objectives: 
1. To provide a molecular understanding on the various drug binding landscape of Zika 
NS3 helicase protein. To accomplish this, the following objectives were outlined: 
1.1. To carry out molecular docking on Zika NS3 helicase in complex with ten ligands and 
subject the best three complexes to subsequent molecular dynamic simulation and some 
post MD analysis. 
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1.2. To analyze the binding interactions between the ligands and protein residues of each 
complex by employing the Molecular Mechanics/Generalized-Born Surface Area 
method (MM/GBSA). 
 
2. To investigate the structural dynamics and conformational changes of the protein both in its 
apo and bounded forms. To achieve this, the following objectives were outlined: 
2.1. To apply various metrics to describe the motion of the ATP binding region of the 
protein. 
2.2. To analyze various stages of the simulation in order to accurately probe the 
dynamics of the loop region. 
 
1.3 Novelty and significance of this study 
This study is the first and only computational study that has been carried out on Zika NS3 
helicase protein to investigate its various ligand binding landscape, structural dynamics and 
conformational changes upon ligand binding. However, no experimental study has reported this 
till date. Several studies had been carried out on other NS3 helicase flaviviruses, such as 
Dengue Virus, Yellow Fever Virus and their inhibitors have been discovered but none on Zika 
Virus. Several studies have reviewed the prevalence of the disease in different countries 
including its manifestation and complications, but none have reported on the molecular dynamic 
simulation of the non-structural protein 3 of the virus. This work is the first investigation into 
the detailed dynamics and structure of the enzyme in response to different ligands. 
The crystal structure of Zika NS3 helicase was reported last year
8,16
 but since, then no serious 
work has been done on the protein. This gap of information forms the basis of this study, 
wherein a comprehensive study of the protein dynamics, free binding energy and landscape 
interaction of the protein is presented. The work presented in this thesis is considered a key 
cornerstone towards further molecular understanding of Zika virus and can serve as a road map 
for drug design and development 
 
1.4 Thesis structure: 
This work is presented in the following five chapters: 
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Chapter 2: Literature Review. This chapter provides a general overview on Zika virus, 
starting with a brief historical background on the Zika virus epidemic and epidemiology. It 
highlights aspects such as the transmission, clinical manifestation, as well as it genome, 
lifecycle, and potential drug targets. The NS3 helicase protein, as a drug target and the focus of 
this work, is addressed in detail, including its structure, and potential inhibitors. 
Chapter 3: Methodology. This chapter details a general introduction to computational 
chemistry and various molecular modeling and simulation techniques, as well as their common 
applications. Theoretical descriptions of the computational methods are included, followed by 
relevant computational tools used in ZIKV research, with a focus on molecular dynamics 
simulations, quantum mechanics, molecular mechanics and docking, binding free energy 
calculations and principal component analysis. 
Chapter 4: Accepted Manuscript. This is a research paper from this study. The paper is 
entitled “Characterizing the Ligand Binding Landscape of Zika NS3 Helicase- Promising Lead 
Compounds as Potential Inhibitors” and accepted in the journal of Future. It addressed 
Objective 1.1 and 1.2. 
 
Chapter 5: Accepted Manuscript.  This is a research paper from this study. The paper is 
entitled “Delving into Zika Virus Structural Dynamics- A Closer look at NS3 Helicase Loop 
flexibility and its Role in Drug Discovery” and submitted to the journal of RCS Advances. It 
addressed Objective 2.1 and 2.2. 
 
Chapter 6: Conclusion. This expounds the concluding remarks of the entire thesis and future 
work plans. 
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Background on Zika virus and Zika NS3 helicase 
 
2.1. Introduction 
This chapter briefly describes the historical background, transmission, manifestation, treatment, 
life cycle and the structure of Zika virus genome. This chapter also highlights the potential drug 
targets and then explains in detail the NS3 helicase protein as the focus of this work including its 
potential inhibitors. 
 
2.2. Brief history and epidemiology of Zika Virus 
The Zika virus (ZIKV) is a positive-sense, single stranded RNA arbovirus belonging to the 
spondweni serocomplex
1,2
. It is an emerging virus that was first discovered in the Zika forest in 
Uganda near lake Victoria in 1947 and was therefore named after the forest
1,2
.The virus was 
isolated in the blood of a sentinel Rhesus monkey during  research on the yellow fever virus, and a 
second isolation from the mosquito Aedes africanus was done at the same forest in January 1948
3
. 
Since then, sporadic isolations have been reported from a variety of mosquito specie in Africa 
(Nigeria, Gabon, Sierra Leone, and Cote d’ Ivoire)2,4, Asia (Cambodia, India, Indonesia, Malaysia, 
Pakistan, Phillipine, Singapore, Thailand and Vietnam), and central America 
5,6
. In 1954, another 
isolation was made from the serum of a 10year old Nigerian girl who presented with fever and 
headache
6
.In 2007, there was an outbreak in Micronesia, which was initially suspected to be 
Dengue Virus (DENV). Several serologic tests were carried out that later confirmed it to be ZIKV. 
Over 70% of the Yap resident were affected by the outbreak, although no death or hospitalization 
was recorded
7
. 
The most recent and devastating outbreak of ZIKV occurred in Brazil at the end of 2015, with an 
estimated 500,000-1,500,000 cases being reported
8
. The virus may have been introduced into 
Brazil by Asian travelers during the 2014 Football World Cup or Participants of the Oceanic 
countries of Va’a World Sprints canoe Championship the same year9,10. Autochthonous cases of 
ZIKV infection has been reported in 26 countries in South America as at January 2016, including 
Mexico, Paraguay, Venezuela, Barbados and Ecuador. Furthermore, ZIKV epidemic was reported 
for the first time in French Polynesia in 2013, with 8,510 suspected cases being reported, since 
which time autochthonous cases have been reported there, including Japan, Norway and France
5
. 
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2.3. Transmission 
Zika virus is mainly transmitted by the female aedes mosquitoe, the first isolation of the virus 
being made from arboreal Aedes africanus. Isolations have been reported from A. apicoargenteus, 
A. luteocephalus, A. aegypti, A.vitattus, and A.furcifer mosquitoes, which all belongs to the sub-
genus Stegomyia
1
. A.aegypti (confined to tropical and subtropical regions) and A.albopictus (found 
in temperate, tropical and subtropical areas) have been implicated in Zika outbreaks, with the latter 
having a wider range than the former
11
. A.albopictus was reported to play an epidemic role in 
Gabon in 2007
12
. ZIKV is said to be epizootic and enzootic in non-human primates, which serve as 
their natural reservoir host (sylvatic cycle)
13
. The mass outbreak of the virus in Brazil has 
suggested that ZIKV can be transmitted through an urban transmission cycle in which the virus 
cycles between its vector and non-wild or domestic animal before affecting humans 
14,15
. Based on 
virology and serology tests been carried out in Africa and Asia, non-human primates, including C. 
albigenajohnstoni, Chlorocebussabaeus, Colobusabyssinicus, Erythrocebuspatas, and 
Pongopygmaeus and mammals such as rodents and zebras, are suggested as possible vertebrate 
hosts for ZIKV transmission
16–18
. 
Non-vector routes have also been reported and include perinatal transmission following the viral 
crossing of the placenta during delivery
19
. The virus has also been detected in amniotic fluid, 
placenta and fetal tissues
20
. Sexual transmission following the detection of the virus in the semen 
of an infected patient has also been reported 
21,22
,  as well as through blood transfusion 
19,23
. The 
viral genome has been detected in urine
24
, saliva
25
 and breast milk
19
, although transmission through 
breastfeeding has not been reported. 
 
2.4. Clinical Manifestation 
The Zika virus infection usually present as asymptomatic, with only one in five cases presenting 
with symptoms
26
. After the incubation period of 3-12days, patients present with acute onset of 
fever, followed by maculo-papular rash on the palm and soles, mild headache, malaise, myalgia, 
arthralgia, conjunctivitis and sometimes, abdominal pain
5,27
. Some of these symptoms are shared 
with other related flavivirus viruses, including dengue virus, yellow fever virus, West Nile, St. 
Louis encephalitis virus and Japanese encephalitis virus
28,29
.Several cases of complications of 
ZIKV has been reported that include 42 cases of Guillian-Barrè Syndrome (GBS), an autoimmune 
disorder in which the immune system attacks healthy nerve cells of the peripheral nervous 
system
10
,  and other neurological conditions that were reported during the epidemic in French 
CHAPTER 2: INSILICO STUDY ON ZIKA NS3 HELICASE 
 
 
9 
Polynesia in 2013
4,30
, which was also noted in Latin America in 2015. Other reported cases 
include, meningoencephalitis in the pacific islands
31
 and myelitis in Guadeloupe
32
. 
The virus is the leading cause of microcephaly by prenatal transmission in South America
33
. This 
is a neurological birth defect in which a baby’s head is significantly smaller than the heads of other 
children of the same sex and age
19
.  The 2015 outbreak resulting in a 20 fold increase in number of 
infants born with this condition, with over 1,200 cases being reported
34
. According to research 
conducted by the Ministry of Health in Brazil, there is an increased risk of microcephaly and 
malformation during the first trimester of pregnancy. The World Health Organization (WHO) 
therefore declared a public health emergency of international concern on the issue of the suspected 
link between Zika and microcephaly on February 1, 2016
35–37
 which ended on November 18, 2017. 
This was due to the high influx of research that has demonstrated the link between the virus and its 
complications
38
. 
 
2.5. Treatment 
There is no specific treatment for the Zika virus, and generally entails providing supportive care 
and treating the symptoms. This might include bed rest, oxygen, adequate rehydration through 
intravenous fluid due to loss of fluid through sweating, and monitoring of vital signs. Antipyretic 
and analgesic, such as acetaminophen or dipyronecan, can be used to reduce the fever and 
arthralgia
3
, while antihistamines can be used to treat the pruritus. The use of aspirin and non-
steroidal anti-inflammatory drugs should be avoided until it has been confirmed that the infection 
is not Dengue or Chikungunya virus to prevent haemorrhagic complications
6,39
. 
 
2.6. Structure of Zika Virus and Genome 
ZIKV is an envelope, icosahedra virus with non-segmented, positive sense, single stranded RNA 
genome of 10.7kb flanked by two untranslated 5’ and 3’ regions that contain a large 
polyprotein
40,41
 (Figure 2.1A). This polyprotein contains more than 3000 amino acids, which 
cleaves into three structural proteins (envelope, E; membrane precursor, PrM; and capsid C) and 
seven Non-Structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5), of which NS3 
helicase protein is an important component for viral replication and RNA synthesis
13
 (Figure 2.1B. 
The three structural proteins are responsible for the efficient regulation of virion assembly
42
. The 
interaction between the precursor membrane (prM) and the envelope protein (E) is important to 
prevent premature virus fusion, while the C protein associates with the RNA to conform the core 
of the virions
41
. 
The non-structural proteins assemble on the endoplasmic reticulum (ER) membranes to form a 
replication complex, which are membrane bound and morphologically distinct in their function 
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and composition
43
. According to the studies carried out by Saiz earlier this year, no studies has 
been carried out regarding the functions of the non-structural protein of ZIKV, although their 
functions can be inferred from other flaviviruses
41
. NS1, NS2A NS4A and NS4B are involved in 
RNA replication, NS2B complexes with NS3 to function as serine protease, NS2A is involved in 
the viral assembly, and NS3 possess RNA helicase and triphosphate activities. NS5 has 
methyltransferase and RNA guanyl-transferase activity, as well as capping and RNA-dependent 
RNA polymerase synthesis activity
13
. 
 
Figure 2.1 (A) Structure of ZIKV genome  (Strain Mr766) (B) Schematic view of the organization 
of ZIKV genome
44
. 
 
2.7 Life Cycle of Zika Virus in a Host Cell 
The life cycle of the Zika virus is similar to other known flaviviruses, being transmitted by a 
vector, the aedes mosquito. When a mosquito bites and sucks the blood of an infected human, it 
becomes infected, after which the virus makes its way into the mosquito’s saliva 45. Once the 
CHAPTER 2: INSILICO STUDY ON ZIKA NS3 HELICASE 
 
 
11 
infected mosquito bites another human, the virus is deposited from the saliva to the blood of the 
new host, who becomes infected. The replication cycle is shown in figure 2.2 
 
Figure 2.2 Replication cycle of Zika Virus
46
 
 
When the virus is deposited into the human host, it finds its way into a cell to replicate. The virus 
becomes attached to the receptor of the host membrane using its envelope (E) protein. The binding 
of the E protein to the receptor induces the virion endocytosis, after which the viral membrane 
fuses with the host’s endosomal membrane. Thereafter, the viral ssRNA is released into the host 
cytoplasm and is then translated into the polyprotein, which cleaves into the structural and non-
structural proteins.
47
. Viral replication takes place at an intracellular viral factory in the 
endoplasmic reticulum and results in the formation of dsRNA, which is transcribed to additional 
ssRNA genome. Following the virion assembly within the endoplasmic reticulum, new virions are 
transported into the golgi apparatus and excreted to the intracellular space via exocytosis, where 
the new virion can infect other cells, thereby continuing the infection cycle
48
(Figure 2.2). 
 
2.8. Potential Drug Target on Zika Virus 
Studies has shown that the structural and non-structural proteins of flaviviruses contain possible 
drug targets for antiviral drugs
49–51
. The structural protein contains the envelope, precursor 
membrane and the capsid protein that plays a vital role in the maturation of the virus and the non-
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structural proteins. 
 
2.8.1. Structural Proteins 
The three structural proteins of flaviviruses are the Capsid (C), Precursor membrane (prM) and 
Envelope (E) membranes, each of which will be described further.  
a. Capsid protein 
The Capsid (C) protein is a small highly systolic basic protein approximately 11kDa that interact 
with the genomic RNA to form the nucleocapsid
52
. It localizes itself to three cellular 
compartments: the endoplasmic reticulum, cytoplasm and the nucleus. It plays a vital role in the 
assembly of the nucleo-capsid and its incorporation into nascent virions
53,54
. The region of the C 
protein that is required for dimerization has been characterized and is induced by RNA. However, 
the development of an in vivo assembly system could lead to identifying compounds that blocks 
the capsid dimerization or capsid RNA-interaction and subsequently inhibit either of this stage
52
. 
b. Precursor membrane protein 
The precursor membrane (prM) is approximately19-21kDa, and is a glycoprotein that is 
translocated into the Endoplasmic Reticulum during polyprotein translation
42
. The prM contains 2 
C terminals, the first anchoring the protein to the ER and the second acts as a signal for luminal 
translocation of envelope protein
55
.It forms a vital part of the flaviviral envelope and assist in 
folding the E-protein. It also contribute to concealing the fusion loop of E to prevent premature 
fusion during virion release
54,56
. 
c. Envelope protein 
The Envelope (E) protein is a large glycoprotein membrane (approximately 53kDa) that 
completely covers the surface of the mature virion. It is responsible for cell surface 
attachment/receptor binding, membrane fusion, and viral entry
57
. The E protein consist of three 
domains; central (called the β-barrel), second (involved in viral fusion during entry) and third 
(immunoglobulin-like domain that is the receptor binding region). Targeting this protein can 
disrupt the viral-host interaction and the entry of the virus into the host, thereby making it an ideal 
target for antiviral
58
.  
 
2.8.2 Non-Structural Proteins 
A few selected non-structural proteins that are relevant to this study and will be discussed in this 
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section include NS1, NS2B, NS3 and NS5. Each of them will be briefly discussed.  
 
 
a. NS1 protein 
The NS1 is a glycoprotein (approximately 46kDa) found within and at the surface of the cell, 
which is then translocated into the ER and released from the envelope protein
57
. It plays an 
important role in viral replication
59
, it has two N-glycosylation sites, the mutation of one or both of 
which can lead to a dramatic defect in RNA replication and subsequent viral production
60
, makes it 
a good target for  designing antiviral compound. 
b. NS2B Protein 
NS2B is a small membrane protein (approximately 14kDa), forms a complex with the NS3 protein 
and serves as a cofactor for NS3 serine protease activity. It has three conserved hydrophobic 
region flanking a hydrophilic domain of approximately 40 residues, this hydrophilic region is 
required to activate the NS3 protease domain
61
. Mutation of the NS2B-NS3 interaction can disrupt 
the serine protease activity, making it an ideal opportunity around which to design an inhibitor
62
. 
c. NS3 Protein 
NS3 is a multifunctional protein (approximately70kDa) and contains several enzymatic activities 
that are involved in viral replication. It contains protease and helicase domains, the  former 
complexes with the NS2B domain to function fully as a serine protease
63
. This serine protease 
domain is located at the N-terminal region of the protein, while the helicase domain is located at 
the C terminal, in addition to the RNA triphosphate (RTPase) activity
57
. The helicase domain 
participates in the RNA replication by displacing viral proteins bound to the dsRNA and disrupting 
the secondary structures that are formed by the ssRNA template
63
. The NS3 helicase has three 
subdomains, with the third subdomain forming the ssRNA binding tunnel. Studies has shown that 
this subdomain has been implicated in mediating the interaction between NS3 and NS5, disrupting 
this interaction being a possible strategy for designing antiviral drugs
64,65
. 
d.  NS5 Protein 
NS5 is the largest (approximately 103kDa) and the most conserved of the flaviviral protein
66
. Its 
N-terminal region comprises of the MTase S-adenosyl-methionine dependent methyltransferase 
(MTase) domain, while its C-terminal region comprises of the RNA-dependent RNA polymerase  
(RdRp) domain
43,67
. The RdRp plays an important role the in the lifecycle of the virus by 
conducting the de novo pathway and generating a viral template during RNA synthesis
68
.The 
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MTase domain has two methylation caps, N7 and 2-O’ methylation, which share a common core 
structured known as “SAM-dependent MTase fold that consist of α/β/α sheet. This protein is 
involved in virus-host interaction and interacts with its host environment
66
. 
2.8.3 Host Target 
In attempting to discover inhibitors for any virus, it is important to consider the cell component of 
the host, which is essential for the lifecycle of the virus and itspathogenesis
52,69
,these  components 
being considered as potential target for developing antivirals. An important aspect in the lifecycle 
of the Zika virus is the entry of the virus into the host, the interruption of which could be a strategy 
to the discovery for an effective inhibitor against this virus
52,58
. Endoplasmic reticulum glycosidase 
are important host enzymes that catalyzes the removal of the three terminal glucose from the 
glycan at the glycosylation site, this being essential for the proper functioning of certain cellular 
and viral proteins
70
. Studies has shown that inhibitors of this enzymes inhibited the infection of 
many envelope viruses
71,72
.Furthermore, some cellular proteins have been reported to bind to viral 
RNA, disruptions such as mutating the binding interactions could be key to developing an 
effective inhibitor
73
. 
 
2.9 Zika NS3 Helicase 
Researchers are currently focusing on the structural and non-structural viral proteins to develop 
drugs
74
, as clinical trials have shown that they are promising targets and play an important role in 
viral replication
49
.In an effort to design an inhibitor against the Zika Virus, it is important to target 
the enzymatic activities that will affect the lifecycle of the virus
75
. One such enzyme is the NS3 
helicase (Figure 2.3), which plays a significant role in viral replication and RNA synthesis. 
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Figure 2.3 Structure of NS3 ZIKV Helicase (PBD 5JMT) 
40 
. Domain 1 (blue: residue 175-332) and 
domain 2 (red: residue 333-481) are seen facing each other, with domain 3 (green: residue 482-
617) lying above the other 2 domains. The ATP binding site is located in the cleft between domains 
1 and 2, and the ssRNA binding site is located at the tunnel that separates domain 3 from the other 
2
75
. 
 
The structure of the Zika NS3 helicase is similar to other flavivirus, such as DENV, Yellow Fever 
Virus, Japanese Encephalitis Virus and Hepatitis C Virus (HCV), but the P-loop in each of these 
flaviviruses differs in their conformation
40
. The  structure is characterized by three domain and two 
binding sites, with a protease domain at the N-terminus and a helicase domain at the C- terminus
43
. 
The two binding sites are the adenosine triphosphate (ATP) and single stranded ribonucleic acid 
(ssRNA) site. The first two domains are structurally similar, and comprises of a six-stranded β-sheet 
surrounded by a number of loop and helices, while domain 3 consist of four α helices bundle and two 
antiparallel β strand43. Domain 3 has been reported to interact with RNA dependent RNA polymerase 
NS5 in other flaviviruses, this helicase structure having two unique features: The P-loop, which is 
essential for NTpase binding, and a positively charged tunnel that interacts with domain 1 and 2. 
2.10 Potential Inhibitors of Zika NS3 Helicase 
Although studies have been released regarding the discovery of Zika viruses
6,26,76
, no FDA 
approved drugs are presently available. To explore Zika NS3 helicase protein, this research 
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utilized some clinically approved flavivirus NS3 small molecule inhibitors that have been proven 
to be effective for other flaviviral diseases. 
2.10.1 Ivermectin 
Ivermectin is a broadly used antihelmetic that has been proved to be a highly potent inhibitor for 
several flaviviruses, such as Yellow fever and dengue. Studies have shown that this drug has a 
good binding affinity towards the NS3 ssRNA binding pocket
77
, and ivermectine was therefore 
used to analyse the RNA binding site of Zika NS3 helicase for this study, and to test it as a 
potential inhibitor of the virus. 
                                 
2.10.2 Purine nucleoside analogues 
In an experiment carried out by Borowski et al (2002), they reported how some purine nucleoside 
analogues inhibited the unwinding reaction of DNA/RNA of the West Nile Virus. They include; 
(1-(2’- deoxy- α -D-ribofuranosyl) imidazo [4,5-d] pyridazine-4,7(5H,6H) dione) (HMC-HO1α), 
1-(2’-O-methyl- α -D-ribofuranosyl) imidazo [4,5-d] pyridazine- 4,7(5H,6H)-dione (HMC-HO4) 
and 1-(β-D-ribofuranosyl) imidazo [4,5-d] pyridazine-4,7(5H,6H)-dione (HMC-HO5)). They 
demonstrated that these nucleoside analogues possess the ability to interfere with the ATPase and 
helicase activity of West Nile Virus and Hepatitis C Virus (HCV) 
78
, which results in  these 
compounds being explored on the ATP site of  Zika NS3 helicase protein. 
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2.10.3 Naphthaquinones 
Compounds with quinone as their core system are said to have positive biological activities 
including antiviral
79
. Naphthaquinones are a promising group of compounds with diverse 
biological activities some of which are used to treat various diseases. Lapachol is a member of this 
group, it exhibits a number of notable biological activities, which include antimalarial, 
antibacterial, trypanocidal, even antiviral. It has been used as a template to develop synthetic 
naphthaquinones, such as α lapachone and β lapachone which have shown considerable biological 
activities including antibacterial, fungal, anticancer, and antiviral activities
80,81
. It was suggested 
that these analogues acts at the level of the topoisomerase I and II enzyme which are vital for 
chromosome structure, DNA transcription and replication
82,83
. In this study, the various 
naphthaquinone compounds were docked into Zika NS3 helicase protein and the best was 
subjected to subsequent analysis.  
                                            
2.10.4 Adenosine analogue NITD008 
Yin et al (2009) reported an adenosine analogue NITD008 that potentially inhibits dengue virus 
both invivo and invitro, and inhibits other flaviviruses, such as West Nile Virus and Yellow Fever 
Virus
84
. This experimental study proves that a nucleoside inhibitor could be developed to treat 
flaviviruses infections. In addition, Lo et al (2016) conducted research on the same adenosine 
analogue and reported how NITD008 was able to inhibit tick-borne flavivirus in an invitro 
experiment
85
. Finally, Yong-Qiang Deng et al (2015) demonstrated how NITD008 is a potent and 
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effective antiviral compound that can be used to design a ZIKV inhibitor
86
. This study therefore 
investigates the structure and conformation of the Zika NS3 helicase protein in an apo and 
bounded form using NITD008. 
2.11. Conclusion 
As an enveloped flavivirus, with a structural and non-structural component, interrupting the Zika 
virus transmission in humans will require drugs that can inhibit viral replication and RNA 
synthesis. This may be possible by exploring the NS3 protein, which is essential in the replication 
and RNA synthesis of the virus. This however, will be critical in understanding how the ZIKV 
NS3 helicase functions structurally, thus aiding in the design of effective inhibitors.  
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CHAPTER 3 
 
Introduction to Computational Chemistry 
 
3.1 Introduction 
Computational chemistry, also known as molecular modeling, is a subfield of theoretical chemistry, 
which focuses on solving chemically related problems by calculation
1
. It deals with the computer 
simulation and modeling systems, such as biomolecules, drugs, and organic or inorganic molecule. 
Computational chemistry consists of molecular mechanics and quantum mechanics, where the former 
is concerned with the physical laws of molecular systems, and the later deals with the behavior of 
matter on an atomic level. This chapter starts with an overview of quantum mechanics, Schrodinger’s 
equation, a brief introduction into the various theoretical and computational tools that best describes 
computational chemistry, which includes Born-oppenheimer’s approximation, quantum mechanics, 
molecular mechanics, and molecular dynamic simulations amongst others.  
 
3.2 Quantum mechanics 
Quantum mechanics is a branch of physics that is concerned with the principles that describes the 
interaction of matter and energy on the atomic and subatomic levels. The term quantum mechanics 
is attributed to Max Planck in 1900 and was derived from the Latin word quanta meaning “how 
much”. J.J Thompson discovered that the laws of classical Newtonian physics cannot be applied at 
the atomic level, resulting in new equations and principles being developed to mathematically 
describe the behavior of matter and energy on a quantum scale. One of the important principles of 
quantum mechanics is the wave particle duality, which states that matter and light can act as either 
waves or particles depending on the circumstance of observation, this being better explained by 
solving the Schrodinger equation.
2
 
 
3.3 Schrodinger’s equation 
Schrodinger equation was developed by Erwin Schrodinger, which predicts the future behavior of 
a dynamic system, and is a fundamental physics equation for describing quantum mechanical 
behavior. The Schrodinger equation has two types, the time dependent and the time independent 
equations, the former describing the quantum system evolution
3
.  
Schrodinger’s equation is given as  
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    Η𝜓 = Ε𝜓      Eq. 3.1 
Where H is the Hamiltonian operator, 𝜓 is a wave function and E is the energy of the state. 
The Hamiltonian equation is also given as the sum of the kinetic (T) and energy potential (V) 
     H = T + V     Eq. 3.2 
Where H is the Hamiltonian operator, T is the kinetic energy and V is the potential energy 
In a more detailed form, Hamiltonian equation can be given as 
 
𝑯 =  −
𝒉𝟐
𝟐𝒎𝒆
∑𝒊𝛁𝒊 
𝟐 − 
𝒉𝟐
𝟐
∑𝑨
𝟏
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𝛁𝑨
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𝟐
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+  ∑𝑨∑𝑩>𝐴
𝒛𝑨
𝒛
𝑩𝒆
𝟐
𝑹𝑨𝑩
  Eq. 3.3 
Where A and B are the nuclei, i and j are the electrons, MA mass of nucleus A, me mass of an 
electron, RAB the distance between nuclei A and B, rij the distance between electrons i and j, 
Z
A 
the charge of nucleus A, rAi the distance between nucleus A and electron i. 
 
3.4 Born-Oppenheimer approximation 
In 1927, Max Born and J. Robert Oppenheimer developed the Born-Oppenheimer approximation, 
leads to a simplification of the Schrodinger’s equation by assuming that the nuclei and the electron 
in a molecule can be separated. It considers the momenta of the electron and nuclei to be of similar 
magnitude and solves the time dependent Schrodinger equation, resulting from Hamiltonian 
equation, by assuming the nuclei of a molecule to be stationary. It then solves the electronic 
ground-state first, calculated the energy of the system and solve for nuclear motion
4
. The energy of 
a molecule is a function of the electron coordinates, and depends on the nuclear coordinate 
parameter that usually defines the geometry, which makes the concept of Potential Energy Surface 
(PES) possible. 
𝑻𝒆𝒍𝒆𝒄 = [− 
𝒉𝟐
𝟖𝝅𝟐𝒎
∑𝒊
𝒆𝒍𝒆𝒄𝒕𝒓𝒐𝒏𝒔 (
𝛛𝟐
𝛛𝐱𝟐
+  
𝛛𝟐
𝛛𝐲𝟐
+  
𝛛𝟐
𝛛𝐳𝟐
)]     Eq. 3.4 
Schrodinger’s equation for fixed nuclei electrons is given as  
𝐇𝐞𝐥𝐞𝐜𝛗𝐞𝐥𝐞𝐜 (𝐫, 𝐑) = 𝐄𝐞𝐟𝐟(𝐑)𝛗𝐞𝐥𝐞𝐜(𝐫, 𝐑)       Eq. 3.5 
Solving this equation for other fixed positions of concern will produce a Potential Energy Surface 
(PES). 
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3.5 Potential Energy surface (PES) 
The Potential Energy surface (PES) is a central concept in computational chemistry that describes 
the energy of a molecule in terms of its structure. It is a graphical or mathematical relationship 
between the energy of a molecule and its geometry
5
. PES is multi-dimensional, and for a diatomic 
molecule is a two-dimensional plot, with the potential energy at the bond distance on the Y axis 
and the internuclear separation at the X-axis. For larger systems, there are many dimensions of the 
surfaces and there are degrees of freedom within the molecule. PES is often represented by the 
illustration in Figure 3.1. 
 
Figure 3.1. Graphical illustration of multi-dimensional potential energy surface
6
. 
 
3.6 Molecular mechanics 
Molecular Mechanics (MM) is a computational method that computes the potential energy surface 
for the arrangement of atoms using potential functions that are derived using classical physics. 
MM aims to predict the structure and physical properties of molecules by calculating the steric 
energy (lowest energy due to conformation) of a molecule, which is assumed to rise from specific 
interactions with another molecule. These interactions have the ability of bonds to stretch and bend 
beyond their equilibrium lengths and angles. In MM, atoms are considered to be spheres, while 
bonds are represented as springs
7
. The deformation of the spring can be used to describe the 
stretching, bending and twisting ability of a bond. Non-bonded atoms also interact via electrostatic 
attraction/repulsion, van der Waals attraction and stearic repulsion. To measure the contribution of 
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each of the interactions in a molecule, the stearic energy of the molecule is given as the sum of the 
energies of the interactions. 
Ε𝑡𝑜𝑡= Ε𝑠𝑡𝑟+ Ε𝑏𝑒𝑛𝑑+ Ε𝑡𝑜𝑟+ Ε𝑣𝑑𝑤+ Ε𝑒𝑙𝑒𝑐      Eq.3.6 
Where Etot is the total energy, Estris the bond-stretching energy, Ebend is the angle-bending 
energy, Etors is the torsional energy, Evdw is the van der Waals energy and Eelec is the 
electrostatic energy. The bond stretching, bending and torsion interactions are called bonded 
interactions, while the Van der Waals and electrostatic interactions are between non-bonded atoms. 
 
3.6.1 Force field 
A force field is a mathematical expression describing the dependence of the energy of a system on 
the coordinates of its particles
8
. It serves as the basic model for molecular mechanics and 
molecular dynamics calculations. Force fields predict the entire energy of a system based upon the 
location and orientation of the atoms and molecules relative to each other
9
. The most commonly 
used force field include AMBER
10
, GROMOS
11
, CHARMM
12
 and NAMD
13
. These force fields 
consists of an analytical form of the interatomic potential and a set of parameters entering into this 
form
8
. The parameters are typically obtained either from ab initio or semi-empirical quantum 
mechanical calculations, or by fitting to experimental data, such as neutron, X-ray and electron 
diffraction, NMR, infrared, Raman and neutron spectroscopy
8
. All force fields have different 
parameters; thus, they must be adjusted to give the results of the forces acting within a molecule. 
The AMBER force field was used for this study, with the General AMBER Force Field (GAFF) 
parameters being applied for ligand parameterization and the standard AMBER force field for the 
protein. 
 
3.7 Molecular dynamic simulation 
Molecular dynamics (MD) is a technique for computationally simulating complex systems 
modeled at the atomic level. MD is the solution of the classical equations of motion for atoms and 
molecules to obtain the time evolution of a system, and is applied to many-particle systems, as a 
general analytical solution is not possible, making it necessary to  use numerical methods and 
computers
14
. It allows the generation of atomic trajectories of many particle systems by integrating 
Newton’s equations of motion for atoms on an energy surface; 
F𝑖 = 𝑚𝑖𝑑2𝑟𝑖 (𝑡)     E.q 3.7  
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𝑑𝑡2 
Where 𝑟𝑖 (𝑡) = (𝑥𝑖 (𝑡), 𝑦𝑖 (𝑡), 𝑧𝑖 (𝑡)) is the (𝑖) particle position vector, 𝐹𝑖 the force acting on 
(𝑖) particle at time t and 𝑚𝑖 the particle mass. 
  
 The aim of computer simulations is to facilitate the understanding of the properties of assemblies 
of molecules in terms of their structure and the microscopic interactions between them, which 
serves as a complement to conventional experiments
15
.Computer simulations act as a bridge 
between microscopic length and time scales and the macroscopic world of the laboratory with 
exact and accurate predictions. It acts as a bridge between theory and experiment, in the sense that 
a theory can be tested by conducting a simulation and the result of the simulation can be compared 
with the experimental result
16
. In MD calculations, the system is either treated with MM or QM 
methods, and the results are usually represented as a trajectory that specifies how the particle 
position and velocity varies with time. 
 
3.8 Molecular docking 
Molecular docking is a valuable tool in Structural Based Drug Design (SBDD), and aim to predict 
the ligand-receptor complex structure using computation methods. To achieve this, a three-
dimensional representation of the protein target must be available, can be obtained either from 
experimental information such as X-ray crystallography or NMR or from a homology model
17
. 
Thereafter, the ligand binding site is located and docking can commence using docking programs 
such as AutoDock
18
, DOCK
19
, PhDOCK
20
, Surflex
20
, FlexX 
21
and GLIDE 
22
. Docking can be 
related to the “lock and key” mechanism that was first proposed by Fischer over 100 hundred years 
ago. Later, the theory of molecular recognition was developed by Koshland to encompass 
conformational changes during the binding event
23
.  Docking entails two things; sampling and 
scoring. Sampling refers to  generating putative ligand binding conformations near a binding site 
of a protein, while scoring predicts the binding tightness for individual ligand conformations with 
a physical or empirical energy function
24
. The ligand-receptor binding energy is calculated as 
follows:  
𝑬𝒃𝒊𝒏𝒅𝒊𝒏𝒈=𝑬𝒕𝒂𝒓𝒈𝒆𝒕+𝑬𝒍𝒊𝒈𝒂𝒏𝒅+𝑬𝒕𝒂𝒓𝒈𝒆𝒕−𝒍𝒊𝒈𝒂𝒏𝒅    E.q 3.8 
 
Docking consists of two types: rigid and flexible docking. In rigid docking, the protein and ligand 
are kept rigid, while in flexible docking, flexibility is allowed either for the protein or ligand, or 
both. The docking method used in this research study was the advanced version of AutoDock, 
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AutoDock Vina
18, as it enables predicting the  flexible ligands’ binding affinity to the NS3 helicase 
protein. 
  
3.9 Binding free energy. 
Free energy calculations have become an important approach in computational chemistry, as it 
enables a detailed investigation of the energetic factors that are responsible for the molecular 
stability or binding affinity of molecular systems
25
. They are typically based on molecular 
dynamics simulations of the receptor--ligand complex. The Molecular Mechanics Poisson–
Boltzmann Surface Area (MM-PBSA)
26
 is a popular approach to estimate the binding free energies 
molecular systems. Other methods that are available to calculate free energies, includes Free 
Energy Perturbation
27
, Replica Exchange Free Energy Perturbation
28
, and Thermodynamic 
Integration
29
. These methods are highly rigorous and demanding, and become more expensive as 
the size of the system increases
26
.  In the MM-PBSA, the binding free energy is the sum of the 
energy and configurational entropy that is associated with complex formation in the gas-phase, and 
the difference in solvation free energies between the complex and the unbound molecules. A brief 
explanation about free binding energy calculation is provided in Chapter 4. 
 
3.10 Principal Component Analysis (PCA) 
Principal Components Analysis (PCA) also known as essential dynamics is one of the 
sophisticated technique used in the analysis of trajectory for understanding the dynamics of 
biological system at molecular level
30
. It describes harmonic atomic displacement and identifies 
major conformational changes in protein structures during MD simulation
31
. PCA describes the 
direction of motion of the protein (eigenvectors) and amplitude their amplitude (eigenvalues)
32
. 
This technique uses sophisticated underlying mathematical principles to transforms a number of 
possibly correlated variables into a smaller number of variables, called principal components
33
. It 
reduces the original data by containing large variables into principal component, the easy spotting 
of the resulting trends, patterns and outliers would have been impossible without PCA
33
. Each 
principal component is a linear combination of the original variables, while the amount of 
information expressed by each principal component is called its variance. Principal components 
are useful, because utilizing only the first few principal components that explain a substantial 
proportion of the total variation can reduce the complexity in interpretation that can be caused by 
having a large number of interrelated variables.  
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Abstract 
Aim: This study aims to provide insight into the binding features of the ATPase and ssRNA 
sites of the NS3 helicase. Methods: Clinically approved flavivirus inhibitors were docked to 
the corresponding active sites of the protein and the three best compounds were validated 
with molecular dynamic simulations. Result: Binding of Ivermectin to ssRNA site and 
Lapachol and HMC-HO1α to the ATPase site allowed for conformational rigidity of the Zika 
NS3 helicase, thus stabilizing residue fluctuations and allowing for protein stability. 
Favorable free binding energies were also noted between compounds and the helicase, thus 
supporting the intermolecular forces at the helicase active site. Conclusion: The 
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pharmacophoric characteristics found in Lapachol, HMC-HO1α and Ivermectin may be 
utilized in the design of a potent hybrid drug that can show efficient inhibition of a multitude 
of diseases including the detrimental co-infection of ZIKV, Dengue and Chikungunya. 
Keywords: 
Zika virus, NS3 helicase, molecular dynamic simulations, free binding energy 
4.1. Introduction 
Zika virus (ZIKV) is a positive-sense, single stranded RNA arbovirus belonging to the genus 
flavivirus and family flaviviridae [1]. The virus was first discovered in a forest in Uganda 
called the Zika forest near lake victoria in 1947, thus coining the virus’s name [2,3]. The 
virus was then isolated in the blood of a sentinel Rhesus monkey during research on the 
Yellow fever virus [4], while a second isolation was done in 1948 at the same site [5]. ZIKV 
virus has a wide geographical distribution including Africa (Uganda, Egypt, Gabon), Asia 
(India, Malaysia, Vietnam, Thailand, Indonesia), and Micronesia [6]. This has been 
demonstrated through viral isolations and serologic studies [7,8]. Although isolations of the 
virus were analyzed, researchers only detected the virus in humans in 1952 when neutralizing 
antibodies were picked up in infected sera. Scientists Boorman and Porterfield subsequently 
studied the transmission of viruses from mosquito to primates and based on further isolations 
from both mosquito and monkey concluded that mosquitoes acted as vectors for ZIKV [1]. 
The rapid spread of the virus across continents is primarily due to vector transmission via the 
Aedes aegypti, Aedes albopictus and Aedes africanus mosquito [2]. These Vectors are 
endemic to tropical and sub-tropical areas. However, due to evolving climates, the 
mosquitoes have expanded their habitat, thus increasing the number of mosquitoes as vectors 
of flaviviruses [9–11]. However, other routes of transmission have been reported, including, 
sexual transmission [10,12], perinatal transmission, and blood transfusion [13]. The 
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symptoms following ZIKV viral infection are mild headache, maculopapular rash, fever, 
malaise, conjunctivitis and arthralgia. These symptoms are shared with other related 
flaviviruses, including Dengue virus, Yellow fever virus, West Nile, St. Louis encephalitis 
virus and Japanese Encephalitis virus [15,16]. The most recent and devastating outbreak of 
ZIKV occurred in Brazil, at the end of 2015. The virus has, to date, rampaged South America 
by being evidenced as a leading cause of microcephaly by prenatal transmission [17]. 
Increasing scientific evidence now shows that the virus can pass through the blood-brain-
barrier and infect neural cells, thus playing a role in diseases such as microcephaly and 
Gullian-Barré Syndrome [18]. 
The ZIKV genome contains 10.7kb single stranded RNA, which contains a large polyprotein, 
which cleaves into 3 structural proteins (envelope, E; membrane precursor, PrM; and capsid, 
C) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5), of 
which, the NS3 helicase plays a pivotal role in viral replication and RNA synthesis. 
Presently, researchers are focusing on the structural and non-structural viral proteins for the 
development of drugs [19], due to their crucial characteristics in viral replication [20]. The 
NS3 helicase (Figure 4.1) has three domains and two binding sites, being the adenosine 
triphosphate (ATP) and single stranded ribonucleic acid (ssRNA) site [21,22]. Inhibiting both 
the ATP and ssRNA sites will be crucial in the inhibition of the NS3 helicase as studies have 
shown that each domain may act independently from the other [23]. However, the close 
proximity of the two binding sites can bring about the possibility of designing a single 
inhibitor that can span both sites [3]. 
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Figure 4.1: Structure of NS3 ZIKV Helicase (PBD 5JMT) [21]. Domain 1 (blue: residue 175-
332) and domain 2 (red: residue 333-481) are seen facing each other and domain 3 (green: 
residue 482-617) lying above the other 2 domains. The ATP binding site is located in the 
cleft between domain 1 and domain 2 and the ssRNA binding site is located at the tunnel that 
separates domain 3 from the other 2 domains [22]. 
 
Due to the rapid spread of the disease on a global scale and the detrimental long-term 
complications, researchers such as Barrows et al (2016)  have turned to ‘repurposing’ 
flavivirus FDA approved drugs rather than the lengthy process of designing and synthesizing 
new drugs [4]. One of the most widely used anthelmintic drugs, Ivermectin, has been 
evidenced to have potent inhibitory effects on flaviviruses by acting as a competitive inhibitor 
of viral ssRNA at the RNA binding site of the NS3 helicase [6,7]. Barrows et al (2016) 
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validated Ivermectin as a potent ZIKV inhibitor in an in vitro screening study, alongside 17 
other FDA-approved flavivirus drugs as well as daptomycin, which had no previous anti-viral 
activity [4]. Another potential drug candidate against ZIKV is the adenosine nucleoside 
analog, NITD008, which has been reported to have competitive inhibitory properties against 
adenosine substrates in vitro and in vivo [8]. However, other reports have also shown 
elevated toxicity levels in preclinical animal testing [9].  
One of the major challenges of ZIKV is its ability to co-infect the host. Multiple cases 
reporting Chikungunya, Dengue and Zika co-infection have been identified, leading to 
potentially exacerbated neurological effects on the host and fetus [10]. By this end, 
identifying potential inhibitors against ZIKV that have already been approved as a Dengue or 
Chikungunya treatment would be beneficial as it would be less toxic than administering 
multiple drugs to a patient [11].  
Although studies have reported ZIKV drug discovery, no FDA approved drugs are presently 
available. There is also a lack in literature regarding the structural and conformational 
features of the protein, thus designing effective novel small drug molecule inhibitors may be 
challenging.  
In this study, we have utilized clinically approved flavivirus NS3 small molecule inhibitors to 
analyze the binding affinity and stability of the ZIKV NS3 domains via Molecular Dynamics 
(MD) simulations, thus mapping out binding hotspots and landscaping interactions of the 
complexes. In addition to this, we will employ Accelerated Molecular Dynamics (aMD) to 
run the simulation for a longer time frame to ensure sufficient conformational sampling and 
accurate physical force field. Accelerated MD is an enhanced sampling technique that 
operates by modifying potential energy, reducing the height of local barriers and accelerating 
transition between different low energy states [24-26]. This will enable the sampling of 
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distinct bimolecular conformations and rare barrier-crossing events that cannot be easily 
accessed in a conventional MD simulation, thereby improving the efficiency of convectional 
MD [27]. 
 
4.2 Computational methodology 
4.2.1. Protein structure preparation 
The crystal structure of the Escherichia coli strain of Zika virus NS3 helicase was retrieved 
from protein data bank (PDB: 5JMT). It was then prepared for molecular docking by 
stripping it off water molecules using UCSF CHIMERA [28] and adding the necessary 
hydrogen atoms using Molegro Molecular Viewer (MMV) [29]. 
4.2.2. Molecular docking 
Molecular docking was performed on 10 ligands: 6 Naphthoquinones (Lapachol, 
Atovaquone, Parvaquone, Buparvaquone, α-Lapachone, β-Lapachone)[30], 3 purine 
nucleoside analogues (1-(2’-deoxy-α-D-ribofuranosyl)imidazo[4,5-d]pyridazine-
4,7(5H,6H)dione)(HMC-HO1α), 1-(2’-O-methyl- α-D-ribofuranosyl)imidazo[4,5-
d]pyridazine- 4,7(5H,6H)-dione(HMC-HO4) and 1-(β-D-ribofuranosyl)imidazo [4,5-
d]pyridazine-4,7(5H,6H)-dione(HMC-HO5)) [31,32] and Ivermectin [33]. Each of the 
compounds were then downloaded from PubChem [34], converted to mol2 format and 
assessed using MMV to ensure that they display the correct bond angle and hybridization 
state. The 2D structures of the ligands are given in the supplementary material (Figure S1). 
Docking was carried out with the Autodock Vina software [35]. Ivermectin was docked at the 
ssRNA binding site, while the rest were docked at the ATPase binding site. The grid box 
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parameters for the 2 sites are given in Figure S2. Of the 10 ligands docked into the active site 
of NS3 protein structure, the best 3 complexes were chosen and subsequently subjected to 
10ns of accelerated-MD.  
4.2.3 Molecular dynamic simulations 
Molecular Dynamic (MD) simulations were performed on the 3 complexes using the graphics 
processor unit (GPU) version of the PMEMD engine provided with the AMBER 14 package 
[36,37].  The Antechamber module was used to generate atomic partial charges for the 
ligands using general amber force field GAFF force field [38]. The protein was described 
using the FF14SB of the Amber force field [39]. The LEAP module in AMBER 14 was used 
to generate topologies for the system by adding protons and counter ions to neutralize the 
system [36]. Subsequently, the complexes were then solvated in a TIP3P [40] octahedron 
water box with 8Å away from the water box edge. The Periodic boundary conditions were 
employed and the particle-mesh Ewald method (PME) in AMBER 14 was used to treat the 
long-range electrostatic interactions with a non-bonding cut-off distance of 10 Å. 
Minimization of the systems were performed with a restraint potential of 500 kcal/mol Å2 to 
treat the solute for 1000 steepest descent steps using the SANDER module of the AMBER 14 
program, followed by 1000 steps of conjugate gradient minimization. The systems were then 
minimized over 1000 steps with unrestrained conjugate gradient. Gradually, the systems were 
heated from 0 to 300 K for 50ps, such that the system maintained a fixed number of atoms 
and a fixed volume, that is, a canonical (NVT) ensemble. 
 The entire system was then equilibrated at 300 K with a 2fs time step in the NPT ensemble 
for 500ps, and Berendsen temperature coupling [39] was used to maintain a constant pressure 
at 1 bar. The SHAKE algorithm [40] was employed on all atoms to constrain the bonds of all 
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hydrogen atoms. With no restraints imposed, an initial production run was performed for 
10ns in an isothermal isobaric (NPT) ensemble using a Berendsen barostat with a target 
pressure of 1 bar and a pressure-coupling constant of 2ps. The systems were subsequently 
subjected to 10ns of accelerated MD using a set of parameters calculated from the potential 
energy of the converged system (Table 4.1). Coordinates were saved every 1ps and the 
trajectories were analyzed every 1ps using the PTRAJ module of AMBER 14. Each system 
was consequently subjected to post molecular dynamic analysis including root mean square 
fluctuation (RMSF), root mean square deviation (RMSD) and radius of gyration (Rg). 
Included in analysis was the ligand-residue profile [25]. Visualization of trajectories was 
conducted in Chimera [28], while the results were analyzed, and plots were generated with 
aid of Origin software [41]. 
Table 4.1:  Calculated parameters for running accelerated molecular dynamics. 
 
ethreshP 
(kcal/mol) 
ethreshD 
(Kcal/mol) 
alphaP 
(kcal/mol) 
alphaD 
(kcal/mol) 
Lapachol System -144728 9424.98 1404.4 355.2 
Ivermectin 
System 
-144600 9465.1 1425.2 355.2 
HMC-
HO1αSystem 
-144698 9455.25 1404.4 355.2 
 
4.2.4 Thermodynamic calculations 
Over the years, molecular mechanics/generalized-born surface area (MM/GBSA) method of 
binding free energy calculations have proved to be a practicable means of understanding the 
ligand-residue landscape binding in various biological macromolecules [42–45]. Therefore, 
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MM/GBSA approach was employed to calculate the binding free energies of Ivermectin, 
Lapachol andHMC-HO1α bound to NS3 helicase protein. To achieve this, 1,000 snapshots 
were extracted from each of the 20ns trajectories. The following equation describes the 
calculations of binding free energy. 
∆Gbind=Gcomplex-Greceptor-Gligand(1) 
∆Gbind=Egas+Gsol-TS (2) 
Egas=Eint+Evdw +Eele(3) 
Gsol=GGB+GSA (4) 
GSA=γSASA (5) 
The term Egas denotes the gas-phase energy that consists of the internal energy Eint, 
Coulomb energy Eele, and the van der Waals energies Evdw. Egas was directly estimated 
from the FF14SB force field terms. The solvation free energy, Gsol, is estimated from the 
energy contribution from the polar states, GGB and non-polar states, GSA. The non-polar 
solvation energy, GSA, is determined from the solvent accessible surface area (SASA) using 
a water probe radius of 1.4 Å, whereas the polar solvation, GGB, contribution is estimated by 
solving the generalized born (GB) equation. S and T denote the total entropy of the solute and 
temperature, respectively. 
4.2.5. Per-residue energy decomposition analysis 
Per-residue free energy decomposition was carried out to obtain the contribution of each 
residue to the total binding free energy profile between the inhibitors Ivermectin, Lapachol 
and HMC-HO1α with the NS3 helicase protein. This was achieved using the MM/GBSA 
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method in AMBER 14[25]. 
4.3. Results and Discussion 
4.3.1 Docking result and validation 
Molecular docking is one of the routinely used methods in molecular modeling and drug 
design. It is used to predict the conformation of small molecule (ligand) within the 
appropriate binding site, making it a valuable tool in drug discovery [46,47]. Furthermore, 
molecular docking ranks docked compounds based on the binding affinity of the ligand to the 
receptor (Figure S3). 
In this study, 10 compounds were chosen to dock into the NS3 helicase based on their 
inhibitory characteristics at flavivirus ATPase/ ssRNA sites [30,31,33]. Of the 10 compounds, 
the best 3 were chosen for subsequent conformational and binding mode analysis. Lapachol 
and HMC-HO1α were chosen from the naphthoquinones and purine nucleoside analogues 
respectively because they portrayed the most optimal docked conformation from the 
molecular docking studies that were carried out. Ivermectin was docked into the ssRNA site 
due to its high potency as a flavivirus inhibitor [33,48]. 
Validation of molecular docking was done by superimposing each of the docked complexes 
with the PDB structures of their natural substrates for ssRNA and ATPase site (PDB code: 
5GJB and 5GJC). This was also achieved by comparing the RMSD of each ligand with the 
natural substrate. The best conformation with the lowest R.MSD (< 1.5 Å) value for each 
ligand were chosen. The results of the superimposition are shown in Figure 4.2. (5JMT- 
green, 5GJB and 5GJC - magenta, ATP and RNA- red, Lapachol, HMC-HO1α and 
Ivermectin –blue). 
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Figure 4.2: 2D structure, docked complexes and validation of the docked complexes. 
4.3.2 Molecular dynamics simulation and post molecular dynamics analysis  
A frequently overlooked side of molecular docking is the flexibility of the binding target. The 
ligand and receptor usually undergo conformational changes before binding and sometimes 
the ligand fits in with little mobility. To ensure the stability of the complex, the 3 complexes 
were subjected to aMD [47,49,50]. 
4.3.2.1 Systems stability 
The stability of the systems was investigated by assessing the Root Mean Square Deviation 
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(RMSD) regarding the Cα-backbone atoms of the 3D structure during the simulation (Figure 
4.3). Equilibrium was attained after 2,000ps and the overall average RMSD value for 
Lapachol, HMC-HO1α and Ivermectin measured 0.98Å, 0.97Å and 0.95Å respectively. The 
results at the ATPase site exhibited similar stability between the HMC-HO1α-ATPase system 
and the Lapachol-ATPase system, whereas, the Ivermectin-ssRNA complex demonstrated the 
lowest average RMSD from all three systems. This is indicative of a more stable complex, 
justifying Ivermectin as a potent flavivirus inhibitor. The RMSD plot further postulates that 
the binding of the three ligands at two different active sites of the protein still allowed for 
conformational rigidity compared to the unstable free protein, which yielded an elevated 
average of 1.76Å. It can therefore be deduced that all three ligands allowed for structural 
stability of the NS3 Helicase protein. 
 
Figure 4.3: C-alpha RMSD backbone Plot for NS3 Helicase free and ligand bound 
conformations. The ligands Lapachol, HMC-HO1α and Ivermectin are seen to stabilize the 
protein as compared to the fluctuating free protein. 
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4.3.2.2 Root Mean Square Fluctuations (RMSF) 
Root Mean Square of Fluctuations (RMSF) were analyzed to show the mobility of each of the 
residues found in the protein, thereby giving an insight into the flexibility of the protein [51]. 
Figure 4.4 depicts the RMSF of the residues for each system for the duration of the 
simulation. High fluctuations were observed at certain residues for each of the systems, with 
the free protein showing the greatest fluctuations during the simulation (1.61Å). All three 
ligand-bound systems showed C-α residue fluctuations at residues 72-79 and 409-411. The 
HMC-HO1α-ATPase system specifically showed flexibility at the “172-176” region, whereas 
the Ivermectin-ssRNA illustrated the lowest fluctuations of all four systems. This correlates 
with the RMSD stability of the systems, demonstrating the free protein to have highly 
unstable residues with large fluctuations compared to the ligand-bound systems. The RMSF 
of Ivermectin also correlated with the RMSD plot, illustrating a relatively stable system after 
ligand binding.   
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Figure 4.4: RMSF Plot for Lapachol, HMC-HO1α and Ivermectin systems. (A) Lapachol 
(0.88Å) showed a higher stability at the ATPase site compared to HMC-HO1α (0.90Å) while 
Ivermectin (0.85Å) showed the most favorable stability of all the systems, (B) NS3 Helicase 
residue flunctuations at regions “72-79” loop (Navy), 2- the “172-176” helix (Gold) and 3- 
the “409-411” loop (Magenta). 
 
4.3.2.3 Radius of Gyration 
To further validate the stability of the systems, the overall protein shape and folding was 
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measured by analyzing the radius of gyration (Rg) of the protein. This gave an insight into 
the distribution of C-α atoms within the protein [51,52]. The plots for all the systems are 
shown in Figure 4.5. From the graph, a difference can be seen in the compactness of the three 
systems from the beginning of the simulation. Ivermectin shows a lower average Rg (22.23Å) 
when compared to HMC-HO1α (22.30Å) and Lapachol (22.33Å), indicating that Ivermectin 
exhibits a very good structural stability at the ssRNA site when it binds to the ZIKV NS3 
helicase. Also at the ATPase site, the result indicates that HMC-HO1α is more compact and 
therefore exhibit more stability than Lapachol. The Rg of the Apo protein correlates with the 
RMSD and RMSF results, showing a wide distribution of C-α atoms for the duration of the 
simulation, thus indicating unstable fluctuations of the protein’s residues in the absence of a 
ligand.  
 
Figure 4.5: Radius of gyration plot for Lapachol, HMC-HO1α and Ivermectin systems when 
compared to the free protein. 
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4.3.2.4 Free Energy Calculations and Residue-Ligand Interaction Network 
Studies have shown that free binding energies calculations are important parameters for the 
validation of ligand-protein binding [43]. Based on the Systems’ stability, we can deduce that 
during the simulation, binding of the three best-docked molecules, being, Lapachol, HMC-
HO1α and Ivermectin, stabilized the fluctuating free protein. This may be due to non-
covalent interactions taking place between the ligands and the active site’s residues. To 
estimate the binding affinities of each of the ligands to the protein, the binding free energies 
were calculated using the Molecular Mechanics/Generalized-Born Surface Area method 
(MM/GBSA) [54]. Table 4.2 summarizes the binding free energy of HMC-HO1α-ATPase 
and Lapachol-ATPase systems to be -42.81kcal/mol and -39.32kcal/mol respectively. The 
non-polar solvation (-103.51kcal/mol) contributed greatly towards the total binding free 
energy of HMC-HO1α-NS3 helicase system while other favorable binding contributions also 
came from intermolecular electrostatic interactions (-62.53kcal/mol) and van der Waals 
interactions (-40.98kcal/mol). Lapachol-NS3 helicase system had its greatest binding 
contribution from non-polar solvation energy (-65.96kcal/mol), followed by van der Waals 
interactions (-38.23kcal/mol) and then intermolecular electrostatic interactions (-
27.73kcal/mol). A polar solvation of 60.69kcal/mol and 26.64kcal/mol for HMC-HO1α-NS3 
helicase system and Lapachol-NS3 helicase system respectively were also observed. This 
indicates that HMC-HO1α has a preferable binding energy than Lapachol at the ATPase site. 
Ivermectin had a relatively higher binding energy (-84.56kcal/mol) at the ssRNA site with the 
greater energy contribution from the non-polar solvation (-136.32kcal/mol) and van der 
Waals interactions (-104.36kcal/mol). 
The active site residues of proteins are important for the protein’s functionality; therefore, it 
is important to understand the interactions of these potential inhibitors with the amino acids 
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residues in the protein [52]. To gain more insight into the contribution of each residue 
towards the binding of the ligand, per residue interaction energy decomposition analysis was 
carried out on the three systems.  
Table 4. 2:  Binding free energy analysis (kcal/mol) for inhibitor- NS3 helicase complexes. 
 
 
Lapachol-ATPase System 
At the ATPase binding site, Lapachol illustrated a favorable energy contribution with 
residues Glu112 (-3.05kcal/mol), sharing the highest total energy, while other contributions 
came from residues Leu20 (-0.24kcal/mol), Gly23 (-0.29kcal/mol), Ala24 (-0.25kcal/mol), 
Glu57 (-0.30kcal/mol), Ala43 (-0.32kcal/mol), Asn243 (-0.89kcal/mol) and Arg285 (-
0.8kcal/mol). However, Lys26 (0.45kcal/mol) and Arg288 (0.8kcal/mol) showed unfavorable 
energy contributions (Figure 4.6). 
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Figure 4.6: Free energy decomposition and ligand-residue interaction network at the ATPase 
site of the Lapachol- NS3 Helicase system. 
HMC-HO1α-ATPase System 
As evident from Figure 4.6 and 4.7, HMC-HO1α and Lapachol interact with the ATPase 
active sites residues by forming a hydrogen bond with residue Arg285 and hydrophobic 
interactions with residues His21, Gly23, Glu112 and Ala143. In addition, HMC-HO1α 
exhibited hydrophobic interactions with residues Pro22, Lys26, Gly25, Arg28, and Asn243. 
Subsequent to HMC-HO1α binding at the ATPase site, significant energy contributions came 
from residues Leu20 (-1.412kcal/mol), His21 (-1.24kcal/mol), Pro22 (-1.75kcal/mol), Gly25 
(-1.55kcal/mol), Lys26 (-1.40kcal/mol), and Thr27 (-2.87kcal/mol), with the highest 
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contribution coming from Glu112 (-4.08kcal/mol), while the unfavorable energy 
contributions came from residue Arg285 (0.26kcal/mol). 
 
 
Figure 4.7: HMC-HO1α docked into the ATPase site of Zika NS3 helicase, illustrating 
ligand-residue interactions and active-site residue energy contributions. 
The ligand-residue interaction network elucidates on the binding interactions between 
Ivermectin and the ssRNA active site residues (Figure 4.8), forming a hydrogen bond with 
Arg214 and hydrophobic interactions with residues Ser94, Leu319, Asp117, Val369, Pro368, 
Thr235, Met240, Glu218, Lys215, Ala90 and Met362. The plot also reveals that residue 
Arg214 (-5.84kcal/mol) had the highest total energy contribution to the binding of Ivermectin 
to the NS3 helicase protein at the ssRNA site. Other favorable energy contributions came 
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from residues Ala90 (-1.48kcal/mol), Ser119 (-2.464kcal/mol), Thr235 (-1.52kcal/mol), 
Asp236 (-1.65kcal/mol), Leu319 (-1.11kcal/mol), Met 362 (-1.87kcal/mol), Pro368 (-
1.14kcal/mol) and Val369 (-1.32kcal/mol) while the unfavorable energy contribution came 
from Asp117 (3.0kcal/mol). 
 
 
Figure 4.8: Free energy decomposition and ligand-residue interaction network at the ssRNA 
site of the Ivermectin- NS3 Helicase system. 
 
 
 
CHAPTER 4: CHARACTERIZING THE BINDING LANDSCAPE OF ZIKA NS3 HELICASE 
 
 
56 
4.4. Conclusions 
In this study, we report the binding analysis of three potential inhibitors of Zika NS3 helicase 
at the ATPase site (Lapachol and HMC-HO1α) and ssRNA site (Ivermectin).  Results 
showed that the binding of Ivermectin to ssRNA site and Lapachol and HMC-HO1α to the 
ATPase site allows for conformational rigidity of the Zika NS3 helicase, thus stabilizing 
residue fluctuations. The interactions between the active site residues and ligands allowed for 
key structural flexibility at two loop regions of the NS3 helicase, thus allowing for protein 
stability and a possible structural mechanism of action for competitive inhibition of natural 
substrates.  
This study aims to contribute toward the repurposing of potent flavivirus inhibitors against 
the devastating ZIKV epidemic. This strategy overcomes the concept of “shooting the dark” 
with experimental screening as the compounds utilized in the study have already been 
synthesized, thus reducing the drug discovery time-line. These potential inhibitors have been 
pre-clinically tested against other arboviruses and have proven to be effective [6,12–14]. 
Drugs such as Ivermectin have multiple functions, including anti-parasitic and more recently 
anti-viral properties [7,11,15]. Lapachol and HMC-HO1α have been shown to have potent 
effects as flavivirus inhibitors including Dengue and Yellow fever virus[13].  
The findings of this study provide fundamental insights toward the structural dynamics of the 
two active site regions on the NS3 Helicase and the ligand-receptor interaction network. The 
pharmacophoric characteristics found in Lapachol, HMC-HO1α and Ivermectin may be 
utilized in the design of a potent hybrid drug that is able to show efficient inhibition of a 
multitude of diseases including the detrimental co-infection of ZIKV, Dengue and 
Chikungunya. 
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4.5. Future Perspective  
To our knowledge, this is the first account of detailed computational investigations aimed to 
provide an insight into the binding features of Lapachol, HMC-HO1α and Ivermectin to 
ZIKV NS3 helicase. Based on the structural dynamics of the two active site regions on the 
NS3 Helicase and the ligand-receptor interaction network, it may be noted that the chemical 
characteristics found in these flavivirus inhibitors play a fundamental role in releasing a 
potent multi-purpose inhibitor against arboviruses. This will allow for pregnant females in 
endemic areas to take the drug as a precautionary measure against arboviruses such as 
Dengue and ZIKV. By having a lower toxicity and higher efficiency, a multi-purpose drug 
will be safe to consume by pregnant females and may diminish the risk of drug resistance due 
to the multiple diseases it is effective against. Distribution on a global scale and at lower cost 
compared to a vaccine that may need optimal storage conditions.  
4.6 Summary point 
 The Zika virus (ZIKV) has emerged as a pathogen of major health concern. The rapid 
spread of the virus has led to an uproar in the medical domain as scientists frantically 
race to develop effective vaccines and small molecules to inhibit the virus. 
 Targeted therapy against specific viral maturation proteins is necessary in halting the 
replication of the virus in the human host, thus decreasing host–host transmission. 
 ZIKV co-infection with dengue and chikungunya has caused major concern in the 
scientific community due to the detrimental fetal neurological effects it leads to. 
 Scientists have now turned to ‘repurposing’ Flavivirus US FDA approved drugs 
rather than the lengthy process of designing and synthesizing new drugs. 
 Multipurpose drugs such as Ivermectin, Lapachol and HMC-HO1α have proven to 
have favorable inhibitory effects on the ZIKV NS3 helicase enzyme. 
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 Free energy calculations and residue–ligand interaction networks have shown 
Lapachol, HMC-HO1α and Ivermectin to trigger key structural flexibility at two-loop 
regions of the NS3 helicase. 
 These flexible loops present a possible structural mechanism for competitive 
inhibition of natural substrates. 
 The pharmacophoric characteristics found in Lapachol, HMC-HO1α and Ivermectin 
may be utilized in the design of a potent hybrid drug that is able to show efficient 
inhibition of a multitude of diseases including the detrimental co-infection of ZIKV, 
dengue and chikungunya. 
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Abstract 
The Zika virus has emerged as a pathogen of major health concern. The rapid spread of the virus 
has led to an uproar in the medical domain as scientists frantically race to develop effective 
vaccines and small molecules to inhibit the virus. In the past year, there has been a flood of Zika 
knowledge published including its characteristics, transmission routes and its role in disease 
conditions such as Microcephaly and Gullian-Barŕe syndrome. Targeted therapy against specific 
viral maturation proteins is necessary in halting the replication of the virus in the human host, 
thus decreasing host-host transmission. This prompted us to investigate the structural properties 
of the Zika NS3 Helicase when bound to ATP-competitive inhibitor, NITD008. In this study, 
comparative molecular dynamic simulations were employed for Apo and bound protein to 
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demonstrate the molecular mechanism of the Helicase. Results clearly revealed that NITD008-
binding caused significant residue fluctuations at the P-loop compared to the rigid nature of the 
Apo conformation. The NITD008-helicase complex also revealed residues 339-348 to transition 
from a 310-Helix to a stable α-helix. These protein fluctuations were verified by investigation of 
dynamic cross correlation and principal component analysis. The fundamental dynamic analyses 
presented in this report is crucial in understanding Zika NS3 Helicase function, thereby giving 
insights toward an inhibition mechanism. The information reported on the binding mode at the 
ATPase active site may also assist in designing of effective inhibitors against this detrimental 
viral target. 
Keywords: 
Zika NS3 Helicase, ATPase active site, Molecular dynamic simulations, P-Loop Flexibility. 
 
5.1 Introduction 
The re-emerging Zika virus (ZIKV) has evolved into a catastrophic epidemic over the past year, 
with scientific community announcing that the long-term effects associated with the virus will 
have to be dealt with in the decades to follow 
1
. The virus was declared an international public 
health emergency by the World Health Organization 
2
, based on growing evidence of the virus 
being linked with congenital neurological diseases such as Guillain-Barŕe, cranial nerve 
dysfunction and Microcephaly 
3,4
. The ZIKV made its devastating re-appearance in Brazil and 
has now spread on a global scale, with an estimated 75 countries with reported mosquito-borne 
ZIKV transmission as of December 2016 
5
. 
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Zika virus is an arthropod-borne flavivirus initially discovered in the Zika forest area of Uganda 
in 1947 
6
. Of the flavivirus genera, ZIKV is most closely related to the Spodweni virus from the 
Spodweni group; however, ZIKV shares structural similarities with other flaviviruses, including 
Dengue virus and West Nile virus 
7
. The ZIKV genome is made up of structural proteins, being 
the capsid, precursor membrane and envelope form the viral particle and seven non-structural 
proteins, being NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5, which participate in the 
replication of the RNA genome, virion assembly and invasion of the innate immune system 
8–10
. 
In our previous review, we explicated on the key viral target proteins, including the 
multifunctional viral replication NS3 helicase protein
11
. The ZIKV helicase comes from the 
superfamily helicases, SF2 
12
, with the inhibition of either one of the binding sites, the RNA-
binding groove or the ATP-binding site (Figure 1), leading to the virus becoming incapable of 
sufficient maturation and replication. The structural characteristics of the ZIKV NS3 protein 
includes three domains: domain I (residues 182-327), domain II (residues 328-480) and domain 
III (residues 481-617), as well as a P-Loop (residues 196-203) which is located at the ATP-
binding site of domain I 
12,13
.  
The co-crystallization of MnATP
-2 
and RNA with ZIKV helicase, reported by Tian et al (2016) 
and Cao et al (2016), have paved the way to understanding the mechanism by which these 
substrates bind to the enzyme, initiating viral RNA replication 
14,15
. Despite the flood of 
integrated knowledge on ZIKV over the past year, the molecular and structural mechanism for 
helicase inhibition is yet to be established 
12
.  
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Figure 5.1: Cartoon and surface representation of the three domains of the ZIKV helicase and the 
two active-binding regions (yellow) that form profound hydrophobic cavities in the electrostatic 
surface area, allowing ATP and ssRNA to bind.  
Another battle being fought by researchers is the discovery of new modes of transmission of the 
virus, from initially being transmitted from vector to host, to now being inclusive of blood 
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transfers from host to host as well as secondary sexual transmission 
16–18
. This has allowed for 
rapid diffusion of the virus between continents. In the plethora of strategic characteristics of the 
virus, its ability to target neuronal cells has been one of the most problematic tasks that 
pharmaceutical chemists have had to overcome 
19–24
. The design of ZIKV inhibitors will not only 
need to be target-specific, effective and have minimal toxicity, but it will also have to pass 
through the blood-brain-barrier 
25
. 
Although there are currently vaccine clinical trials under way, there are still no FDA approved 
small molecule inhibitors against the virus 
26–30
. This may be due to many reasons including 
time-consuming experimental testing of large libraries of compounds or minimal literature 
available on the functionality of the virus in host cells. These possible barriers have prompted us 
to utilize computational drug design tools, such as molecular dynamic (MD) simulations to 
explore the conformational landscape of this biological system’s ATP-binding region. The 
crystallographic structures have revealed evidence of residue mobility, including the rotation of 
motor domains, however, the precise structural characteristics of the helicase upon small 
molecule binding, is yet to be determined 
12,31–36
.  
In this study we investigate the conformational changes at the ATP-binding region after a 130ns 
MD simulation of the free enzyme state as well as a NITD008-bound complex 
37
. This study will 
be critical in understanding how the ZIKV NS3 helicase functions structurally, thus aiding in the 
design of effective, target-specific inhibitors.  
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5.2 Computational Methods 
5.2.1 System Preparation  
The ZIKV NS3 helicase in complex with ATP and a magnesium ion (PDB code: 5GJC)
14
 was 
obtained from RSCB Protein Data Bank 
38
. The 3-D structure of the experimental ZIKV 
inhibitor, NITD008, was obtained from PubChem
39
 and prepared on Molegro Molecular Viewer 
(MMV) 
40
. In the ZIKV crystal structure of the ATP-bound helicase, residues A247-S253 were 
absent, thus the free enzyme (PDB code: 5JMT)
13
 was utilized in the docking of NITD008. Deng 
et al (2016) reported conclusive in vivo evidence of the inhibition of ZIKV by NITD008. The 
compound is classified as an adenosine nucleoside analog that competitively inhibits ATP, thus 
sharing an active site 
37
.  
5.2.2 Molecular Docking 
Molecular docking is a conventional method in computational chemistry which is utilized in the 
prediction optimized geometric conformations of a ligand within an appropriate binding site 
41
. 
The Molecular docking software utilized included Raccoon 
42
, Autodock Graphical user interface 
supplied by MGL tools 
43
 and AutoDockVina 
44
 with default docking parameters. Prior to 
docking, Gasteiger charges were added to NITD008 and the non-polar hydrogen atoms were 
merged to carbon atoms. Water molecules were removed, and polar hydrogen was added to the 
crystal structure of the NS3 helicase. NITD008 was then docked into the ATPase binding pocket 
of the NS3 helicase (by defining the grid box with spacing of 1 Å and size of 32 × 26 × 30 
pointing in x, y and z directions respectively). Due to the lack of experimental data describing 
ZIKV approved inhibitors, validation of molecular docking based on the lowest energy pose 
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becomes unreliable 
45
. To overcome any experimental bias, the five best conformational poses, 
based on binding affinities (kcal/mol), were subjected to MD simulations. 
5.2.3 Molecular Dynamic (MD) Simulations 
Molecular dynamic (MD) simulations provide a robust tool to explore the physical movements 
of atoms and molecules, thus providing insights on the dynamical evolution of biological 
systems. The MD simulation was performed using the GPU version of the PMEMD engine 
provided with the AMBER package, FF14SB variant of the AMBER force field 
46
 was used to 
describe the protein.  
ANTECHAMBER was used to generate atomic partial charges for the ligand by utilizing the 
Restrained Electrostatic Potential (RESP) and the General Amber Force Field (GAFF) 
procedures. The Leap module of AMBER 14 allowed for addition of hydrogen atoms, as well as 
Na
+
 and Cl
-
 counter ions for neutralization to both the Apo- and Bound system.  
Both systems were then suspended implicitly within an orthorhombic box of TIP3P water 
molecules such that all atoms were within 10Å of any box edge. 
An initial minimization of 2000 steps were carried out with an applied restraint potential of 500 
kcal/mol Å
2 
for both solutes, were performed for 1000 steps using a steepest descent method 
followed by a 1000 step of conjugate gradients. An additional full minimization of 1000 steps 
were further carried out by conjugate gradient algorithm without restrain. 
A gradual heating MD simulation from 0K to 300K was executed for 50ps, such that the system 
maintained a fixed number of atoms and fixed volume, i.e., a canonical ensemble (NVT). The 
solutes within the system are imposed with a potential harmonic restraint of 10kcal/mol Å 2 and 
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collision frequency of 1.0ps-1. Following heating, an equilibration estimating 500ps of each 
system was conducted; the operating temperature was kept constant at 300K. Additional features 
such as a few atoms and pressure where also kept constant mimicking an isobaric-isothermal 
ensemble (NPT). The systems pressure was maintained at 1 bar using the Berendsen barostat.  
The total time for the MD simulation conducted was 130ns. In each simulation, the SHAKE 
algorithm was employed to constrict the bonds of hydrogen atoms. The step size of each 
simulation was 2fs and an SPFP precision model was used. The simulations coincided with 
isobaric-isothermal ensemble (NPT), with randomized seeding, constant pressure of 1 bar 
maintained by the Berendsen barostat, a pressure-coupling constant of 2ps, a temperature of 
300K and Langevin thermostat with collision frequency of 1.0ps-2.  
5.2.4 Post-Dynamic Analysis 
The coordinates of the free enzyme and NITD008 complex were each saved every 1ps and the 
trajectories were analyzed every 1ps using PTRAJ, followed by analysis of RMSD, RMSF and 
Radius of Gyration using the CPPTRAJ module employed in AMBER 14 suit. 
5.2.4.1 Binding Free Energy Calculations 
Binding free energy calculations is an important end point method that may elucidate on the 
mechanism of binding between a ligand and enzyme, including both enthalpic and enthropic 
contributions 
47
. To estimate the binding affinity of the docked systems, the free binding energy 
was calculated using the Molecular Mechanics/GB Surface Area method (MM/GBSA) 
48
. 
Binding free energy was averaged over 15000 snapshots extracted from the 130ns trajectory. The 
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free binding energy (ΔG) computed by this method for each molecular species (complex, ligand 
and receptor) can be represented as: 
∆Gbind = Gcomplex − Greceptor − Gligand                                         (1) 
∆Gbind = Egas + Gsol − TS                                                                  (2) 
Egas = Eint + Evdw + Eele                                                                   (3) 
Gsol = GGB + GSA                                                                                   (4) 
GSA = γSASA                                                                                           (5) 
 
The term Egas denotes the gas-phase energy, which consist of the internal energy Eint; Coulomb 
energy Eele and the van der Waals energies Evdw. The Egas was directly estimated from the 
FF14SB force field terms. Solvation free energy, Gsol, was estimated from the energy 
contribution from the polar states, GGB and non-polar states, G. The non-polar solvation energy, 
SA. GSA, was determined from the solvent accessible surface area (SASA), using a water probe 
radius of 1.4 Å, whereas the polar solvation, GGB, contribution was estimated by solving the GB 
equation. S and T denote the total entropy of the solute and temperature respectively.  
To obtain the contribution of each residue to the total binding free energy profile at the ATPase 
site, per-residue free energy decomposition was carried out at the atomic level for imperative 
residues using the MM/GBSA method in AMBER 14 suit.  
The system displaying the most favorable binding interaction and energy contributions were 
subjected to further analysis.  
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5.2.4.2 Dynamic Cross-correlation Analysis (DCC) 
Dynamic cross correlation is a widespread method in MD simulations in which the correlation 
coefficients of motions between atoms of a protein may be quantified 
49
. The dynamic cross 
correlation between the residue-based fluctuations during simulation was calculated using the 
CPPTRAJ module incorporated in AMBER 14. The formula used to describe dynamic cross 
correlation is given below: 
𝐶𝑦 =  
< Δri. Δrj >
(< Δ𝑟𝑖
2 ><  Δ𝑟𝑗
2 >)
1
2
 
The cross-correlation coefficient (Cij) varies within a range of −1 to +1 of which the upper and 
lower limits correspond to a fully correlated and anti-correlated motion during the simulation 
process. Where, i and j stands for i
th
 and j
th
 residue respectively and Δri or Δrj represents 
displacement vectors correspond to i
th
 and j
th
 residue respectively. The generated dynamic cross 
correlation matrix was constructed in Origin software.  
5.2.4.3 Principal Component Analysis (PCA) 
Principal component analysis (PCA) is a covariance-matrix-based mathematical technique that is 
able to demonstrate atomic displacement and the loop dynamics of a protein 
50
. Prior to 
processing the MD trajectories for PCA, the trajectories of the free enzyme (APO) and the 
NITD008-bound complex (Complex) were stripped of solvent and ions using the PTRAJ module 
in AMBER 14. The stripped trajectories were then aligned against their corresponding fully 
minimized structures. PCA was performed for C-α atoms on 900 snapshots each. Using in-house 
scripts, the first two principal components were calculated and the covariance matrices were 
generated. The first two principal components (PC1 and PC2) generated from each trajectory 
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were averaged for both the free-enzyme and NITD008-complex. The first two principal 
components (PC1 and PC2) were computed and a 2 X 2 covariance matrix were generated using 
Cartesian coordinates of Cα atoms. PC1 and PC2 correspond to first two eigenvectors of 
covariant matrices. Origin software 
51
 was used to construct PCA plots. 
5.3 Results and Discussion 
5.3.1 NITD008-NS3 Helicase Complex 
5.3.1.1 Binding of NIT21D008 with ZIKV Helicase 
Research into ZIKV inhibitors has been minimal before 2016. However, NITD008, a flavivirus 
adenosine analogue was evidenced, both in vitro and in vivo, to inhibit ZIKV replication. The 
adenosine nucleoside analogue competes with natural ATP substrates, which are incorporated 
into the growing RNA chain. By this substitution, NITD008 is incorporated into the RNA chain, 
thus terminating the RNA elongation and inhibiting ZIKV maturation 
37
.  
Molecular docking has become a major computational tool that is used to predict the orientation 
of a ligand at a binding site on the receptor. Results from docking often display multiple 
predicted orientations of the ligand within the active pocket 
52
.   
In this study, NITD008 docked at the ATP-binding site in 6 favorable conformations (Figures 
S2-S6), with the highest binding-affinity being -8.2 kcal/mol. Scoring functions often attempt to 
reproduce experimental binding affinities, but most software do not always yield the best 
prediction. Validation of the docked structure with experimentally known drugs was also not 
possible due to the lack of FDA inhibitors against ZIKV 
45,53,54
.  
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In an attempt to improve the binding affinity prediction of NITD008, all 6 predicted complexes 
were subjected to 130ns molecular dynamic simulations, allowing for more realistic receptor 
flexibility in an implicit solvent. Each complex was then analyzed using the accurate, 
MM/GBSA, free binding energy calculation to determine the most favorable pose of NITD008 at 
the NS3 ATPase active site 
47,55–57
.  
5.3.1.2 Free Energy calculations 
The total binding free energy for each of the 6 poses of the NITD008- NS3 helicase complex 
were calculated using the MM/GBSA approach to better understand the various energy 
contributions within the binding pocket and assess which binding pose would show the most 
favorable intermolecular interactions at the helicase active site. Per residue decomposition 
analysis was also assessed and the residue-ligand interaction network of each pose were depicted 
as “ligplot” maps (Figures S2-S6). Of the six systems, the pose with the highest docking score, -
8.2 kcal/mol, showed the most favorable free binding energy (-55.90 kcal/mol) supported the 
molecular docking score, indicating a favorable structural pose of NITD008 at the binding site.  
The thermodynamic energy contribution of NITD008 to the total binding free energy of the 
complex surmounts to the stability of NITD008 in the ATP binding pocket and thus the stability 
of the complex during the simulation. Table 4.1 summarizes the free binding energy of the 
system considering the energies of the NS3 helicase and NITD008.  
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Table 5.1: Summary of free binding Energy contributions to the NITD008-NS3 Helicase system. 
 
 
Figure 5.2 represents the residue interaction plot of NITD008 within the active site. The active 
site residues Gly199, Lys200 and Glu286 formed stable hydrogen bonds with highly 
electronegative oxygen atoms of NITD008. The residues pocketing NITD008 within the active 
site included Gly197, Ala198, Gly199, Lys200, Thr201, Arg202, Glu288, Gly415, Asn417 and 
Arg456. 
 
It was also interesting to note that the most favorable NITD008-pose shared five active residues 
with the ATP-bound helicase reported by Tian et al (2016). The crystal structure of the ATP-
bound helicase showed Lys200 to stabilize the triphosphate of the ATP 
14
. The Lys200 of the 
NITD008-bound helicase showed a similar stabilizing hydrogen bond with the terminal hydroxyl 
group located on the ribose of NITD008.  
 
Energy Components (kcal/mol) 
 
 
 Δ EvdW ΔEelec ΔGgas ΔGsolv ΔGbind 
 
ZIKV 
HELICASE 
 
 
-3429.35 ± 
30.09 
 
 
-28758.51 ± 
159.37 
 
 
-32187.86 ± 
155.05 
 
 
-5121.93 ± 
115.09 
 
 
-37309.79 ± 
71.27 
 
NITD008 
 
-4.69 ±  
0.85 
 
18.12 ± 5.27 
 
13.43 ± 5.28 
 
-221.12 ± 
3.35 
 
-207.68 ± 
3.72 
 
COMPLEX 
 
-37.71 ± 
4.12 
-382.94 ± 
28.72 
-420.64 ± 
28.59 
364.75 ± 
22.80 
-55.90 ± 
7.71 
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Figure 5.2: Energy contributions of the highest interacting residues at the ATPase active site. The 
residue ligand interaction network illustrates stabilizing hydrophobic interactions pocketing 
NITD008 at the active site. The highest energy contribution was a hydrogen bond interaction 
shared between Glu286 and the 3
rd
 oxygen of the ribose component of NITD008. 
Superimposition of NITD008-docked NS3 helicase with the ATP-NS3 helicase complex 
demonstrated both compounds to bind in a hydrophilic conformation despite the carbon and 
acetylene substitutions at N-7 of the purine and the 2’ position of the ribose, respectively (Figure 
5.3). The structural similarities between NITD008 and ATP, as well as the active site residue 
interactions and accurate free-binding energy prompted the further analysis of NITD008-
complex. 
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Figure 5.3: Superimposed conformation of structurally similar NITD008 and ATP docked at 
ATPase site of ZIKV NS3 Helicase. 
5.3.2 Systems Stability 
The length of a MD simulation is paramount when establishing insights into the structural 
dynamics of a biological system. With an extended simulation time, a system is able to reach 
convergence, thus becoming stable. To assure the equilibration of the simulation, the potential 
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energy and temperature where monitored (Figure S1). The average potential energy (-145774 
kcal/mol) was measured at 300K, suggesting a stable conformation at this temperature.  
5.3.2.1 Stability of NS3 Helicase APO and Bound System  
The C-α backbone root mean square deviations (RMSD) were monitored throughout the 130ns 
MD simulation for both the free (APO) enzyme and the complex. Both systems reached 
convergence after 60ns (RMSD deviation < 2 Å). It can be noted that the C-α backbone atoms in 
both systems stabilized after a 40ns time, although, fluctuations in rigidity did increase during 
the 47-52ns period in the NITD008 complex (Figure 5.4). This could possibly be due to the 
occurrence of conformational changes because of the bond interactions taking place between 
NITD008 and the active site residues as seen in the Per-residue energy decomposition. 
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Figure 5.4: C-α backbone RMSD for NS3 Helicase APO enzyme and NITD-complex 
conformation. The average C-α RMSD was calculated to be 3.62 Å and 3.77 Å, respectively. 
Increased fluctuations occurred at 47-52ns in the NITD008-complex. 
5.3.2.2 Conformational Fluctuations of the NS3 Helicase 
To better understand the structural changes that may be occurring upon ligand binding, the root 
mean square fluctuation (RMSF) of the C-α atoms of each residue in the APO system and 
NITD008-complex were calculated. Figure 5.5 clearly demonstrates greater flexibility of 
residues of the NITD008-complex when compared to the APO enzyme. Fluctuations take place 
between residues 198-204, which form distinct hydrophobic and hydrogen bond interactions with 
NIT008D at the active site. This region, the P-Loop, is found in all flavivirus helicases and has 
been shown to have flexibility during binding of ATP 
14
. The P-loop adopts structural 
modifications to accommodate the binding of ATP and Mn
2+
. This flexibility extends greatly in 
comparison to the APO enzyme, thus verifying ZIKV P-loop flexibility upon ligand-binding. 
Other fluctuations occurred in domain II, and I around the ATP-active site, at residues 244-248 
and 325-348.  
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Figure 5.5: The RMSF of APO enzyme and NITD008-complex. The structural flexibility in 
domain I and II is highly attributed to the binding of NITD008 to the ATP-active site. This is 
substantiated by the average RMSF of the NITD008-complex (2.17 Å), which is significantly 
higher than that of the APO enzyme (1.90 Å). 
5.3.2.3 Distribution of Atoms around the NS3 Helicase Backbone 
The radius of gyration around the C-α atoms can measure the shape and folding of NS3 helicase 
before and after NITD008 binding. The radius of gyration measures the distribution of atoms 
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from the center of mass (COM), thus indicating how compact a system is. Both the APO (22.05 
Å) and NITD008 (22.17 Å) showed very similar structural compactness, however, there was an 
atomic distribution in the NITD008-complex from 40-58ns (Figure 5.6). This correlates with the 
escalated instability of the complex at 47-52ns demonstrated in the RMSD plot.  
 
Figure 5.6: The radius of gyration (Rg) plot illustrating the difference in enzyme compactness of 
the NITD008-complex compared to the APO enzyme. 
 
The flexibility calculated from the RMSD, RMSF and Rg encouraged us to explore the dynamic 
structural modifications of the NS3 Helicase after NITD008 binding.  
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5.3.3 Investigation of the Dynamic Structural features ATP-Active Binding Region  
5.3.3.1 Loop Flexibility and Distance metrics 
The ZIKV NS3 Helicase is made up of three known flexible loops that are common to all 
flaviviruses: The P-loop (residues 196-203), the RNA-binding loop (residues 244-255) and the β-
hairpin loop (residues 431-444). These loops may vary in size depending on the type of virus; 
however, they all have the same fundamental structural flexibility.  The RMSF plot demonstrated 
major fluctuations at the P-loop as well as the RNA-binding loop, the β-hairpin loop however, 
showed no significant conformational change compared to the APO enzyme. The plot also 
illustrated a flexible “325-338” region. Figure 5.7 depicts three snapshots of the APO enzyme 
and NITD008-complex, taking at different intervals along the trajectory. Clear conformational 
shifts are illustrated along the trajectory in both APO and bound systems.  
To further investigate the conformational changes of the NS3 Helicase upon ligand binding, 
dynamic cross-correlation matrix (DCCM) analysis was performed at different conformational 
positions of the Cα backbone atoms of the free protein and ligand-bound complex. Highly 
correlated motions of residues are represented in the red to yellow regions, whereas, the 
negative/anti-correlated movements of residue Cα atoms are represented by blue-navy regions. It 
is evident from the correlation map that more globally correlated motion is observed in the case 
of the free protein, confirming conformational shifts after ligand binding. The latter residues of 
the NS3 Helicase, being residues 500-600, displayed anti-correlated movements in both the Apo 
and Bound complex, supporting the residue fluctuations in figure 5. Figure 7 also depicts anti-
correlation motions at residues “340-390”, which may be explained by the snapshots, in which, 
the flexible region in the NITD008-bound complex was converted from a 310-helix to a α-helix. 
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Figure 5.7: Structural Flexibility of the P-Loop (196-203), RNA-binding loop (244-255), and the 
310 Helix (339-348) along the trajectory. The RNA-binding loop (orange) showed the loop 
shifting down in the Apo structure but an upward shift in the NITD008- Helicase complex. The 
P-Loop (Yellow) shifted away from the active site in the bound complex but closed in on the 
active site when no ligand was present. In the Apo structure, the helix-loop-helix stayed, with 
vibrational movement during the simulation, although, in the bound complex, the 310 Helix 
(Pink) was modified into a α-helix due to ligand motional shifts further into the hydrophobic 
pocket. 
 
The P-loop clearly illustrates that when NS3 Helicase is in its APO form and exposed to a 130ns 
simulation, the P-loop closes on the active site by uncoiling the α-helix at Arg203 to form part of 
the loop. The loop tip (Ala198) and the adjacent catalytic residue (Gly451) had an average 
distance of 9.71Å compared to the NITD008-complex distance of 12.75Å, whereby, as NITD008 
becomes more stable at the active site and forms bond interactions, the P-loop is directed away 
from NITD008 and a larger catalytic space becomes available for the ligand as it forms stable 
hydrophobic interactions deeper within the hydrophobic pocket (Figure 5.8). 
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Figure 5.8: Residue fluctuations at the P-Loop region.The Apo enzyme illustrates closing of the 
loop at the active site due to a vacant hydrophobic pocket. Subsequent to ligand binding and the 
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initiation of stabilizing hydrogen and hydrophobic bond interactions, the P-loop shifts down to 
accommodate the ligand, thus increasing the size of the hydrophobic pocket.  
The “325-348” region demonstrates opposing conformational modifications between the APO 
and complex systems compared to that of the P-loop. The Distance between the two catalytic 
residues from the loop tips; residue Ser324 and residue Asn448, measured for the APO and 
NITD008-complex was 6.34Å and 8.34Å, respectively (Figure 5.9). The NITD008-complex had 
a greater distance between the residues due to the unraveling of 2 β-sheets found in domain II. 
This led to a “325-338” loop shift behind the active site and the “339-348” region being modified 
from a 310 Helix to a α-Helix (Figure 7). The 310 Helix conversion could be due to many reasons 
including changes in pH, interactions with other proteins and in this case, ligand binding. The 
ligand-protein interactions lead to distances between nitrogen and oxygen atoms from the protein 
backbone to fluctuate and as NITD008 moved further into the hydrophobic pocket, these 
fluctuations and hydrogen bond conversions caused the 310 helix to convert to an α-helix. These 
changes are important in illustrating the conformational fluctuations upon ligand binding.  
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Figure 5.9: Residue fluctuations at the “325-348” region. The Apo enzyme illustrates widening 
of the loops of the Apo enzyme. The rear loop shifts down as the P-loop closes in on the active 
site. The largest fluctuation is seen after system stabilization at 40-60ns.  The NITD008-Helicase 
enzyme shows instability in both loops throughout the simulations, although, there was no 
widening of the loops as the rear loop shifted back rather than downward movement seen in the 
Apo system. 
5.3.3.2 Principal Component Analysis 
Conformational transitions of the free protein and NITD008-bound complex were characterized 
using PCA, a technique that has been widely employed to present experimentally detected 
conformational variations. Figure 5.10 highlights the motional shifts across two principle 
components in the case of NITD008-bound and unbound NS3 Helicase. It is evident that 
eigenvectors computed from the respective simulations varied immensely between the two 
systems, further elaborating on the dynamic conformational fluctuations from free to ligand-
bound protein. The unbound system shows restricted structural motions of residue Cα atoms, 
whereby the NITD008-bound system shows a larger spatial occupancy, thus substantiating the 
rigidity of the unbound system. This corresponds with the stability of the systems, illustrating 
greater distribution of the atoms around the center of mass and the system stability deviations for 
the NITD008-bound system. Correlation from analysis of both the free and bound protein 
demonstrates structural loop flexibility after binding of NITD008 to the ATPase active site.  
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Figure 5.10: Projection of Eigen values of the Cα backbone, during 130ns simulation, for Apo 
and NITD008-bound conformations of NS3 Helicase along the first two principal components. 
The X- and Y- axis, PC1 and PC2, respectively, represent a covariance matrix after elimination 
of eigenvectors (rotational movements). Each point between the single-directional motions 
represents a unique conformation during the simulation, whereby, similar structural 
conformations overlap in the graph. 
 
 
DELVING INTO ZIKA VIRUS STRUCTURAL DYNAMICS 
92 
 
5.4. Conclusion 
The detailed MD analyses provided in this report demonstrate the structural alterations in ZIKV 
NS3 Helicase loop flexibility subsequent to binding of potent inhibitor, NITD008 
37
. Molecular 
simulations revealed profound motional shifts of the ZIKV P-Loop at the ATPase active site. 
This flexibility was revealed in the RMSF analysis and verified by graphical investigation of the 
loop at different time intervals during the simulation. Investigation into the dynamic cross-
correlation of the unbound and bound systems as well as a plot of conformational poses along the 
first two principal components resulted in strongly significant structural flexibility of the 
NITD008-NS3 Helicase system compared to the rigid unbound protein. The P-loop has 
demonstrated similar motional shifts in other flaviviruses as well as in ZIKV, when natural 
substrate, ATP binds at the active site. The competitive inhibitor, NITD008, has been proven to 
effectively constrain ZIKV replication both in vitro and in vivo. Complex stability measured 
through the 130ns simulation showed consistency of NITD008 at the ATPase active site and 
binding free energy calculations and residue-ligand networks revealed strong stabilizing 
hydrophobic and hydrogen bond interactions pocketing NITD008 in the active site. Further 
conformational changes were illustrated by the “325-338” loop shift behind the active site and 
the “339-348” region being modified from a fluctuating 310 Helix to a more stable α-Helix.  
Crystallographic studies have identified the P-loop, specifically Lys200, to be critical in 
stabilizing the triphosphate moiety of an NTP, thus allowing flexibility upon ligand binding and 
activation 
12–14
. To augment these key findings, Lys200 showed strong hydrogen bonds with the 
NTP-analogue, NITD008. Other active-hotspot residues included P-loop residues: Gly197-
Arg202, Ala198, Glu286, Gly415, Asn417 and Arg456. The insights demonstrating the above 
binding landscape of the ZIKV NS3 Helicase will aid researchers in the identification of 
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targeted-small molecule inhibitors through structure based drug design and to utilize 
pharmacophore models in screening for effective drugs with minimal toxicity.   
Future experimental analysis is needed to fully understand these loop shifts toward inhibition of 
the enzyme as well as investigations into possible mutational resistance as seen in other 
flavivirus Helicase NTPase sites. 
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CHAPTER 6 
 
Conclusion and future recommendations 
 
This chapter outlines the general conclusion of the study as well as recommendations for future research 
based on its findings. 
6.1. General conclusions 
The research study reported in this thesis is an in-silico studies on Zika NS3 Helicase: bedrock for 
antiviral drug design. It aims are (a) to provide a molecular understanding on the various drug binding 
landscape of Zika NS3 helicase protein (b) to investigate the structural dynamics and conformational 
changes of the protein. This work has accomplished the aims of this study; the results from this work 
confirmed the following conclusions: 
The results of Objective 1 found that: 
1. Ivermectin, HMC-HO1α and Lapachol emerged as the best three ligands out of the 10 clinically proven 
flaviviral NS3 small molecule inhibitor that were docked into the Zika NS3 helicase protein.  
2.The binding of Ivermectin to ssRNA site and Lapachol and HMC-HO1α to the ATPase site allows for 
conformational rigidity of the Zika NS3 helicase, thus stabilizing residue fluctuations. 
3.Ivermectine interacted with the protein at the ssRNA binding site through hydrophobic interactions, and 
hydrogen and covalent bond formation with the protein residues. While HMC-HO1α and Lapachol 
interacted with the ATPase active sites residues by forming hydrogen bonds and hydrophobic 
interactions. However, HMC-HO1α also formed a covalent interaction with residue Arg288 of the 
protein. 
4. Free binding energy calculations showed Ivermectin to have a relatively higher binding energy (-
84.56kcal/mol) at the ssRNA site than HMC-HO1α (-42.81kcal/mol), and Lapachol (-39.32kcal/mol) at 
the ATPase site. Furthermore, residue Glu112 had the highest energy contribution to the binding of 
HMC-HO1α (-4.08kcal/mol), and Lapachol (-3.05kcal/mol) to NS3 helicase protein binding at the 
ATPase site, while residue Arg214 had the highest total energy contribution to the binding of Ivermectin 
(-5.84kcal/mol) to the NS3 helicase protein at the ssRNA site. 
The results of Objective 2 found that  
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5. Investigating the dynamic cross-correlation of the unbound and bound systems resulted in strongly 
significant structural flexibility of the NITD008-NS3 Helicase system compared to the rigid unbound 
protein. This include:  
i) The RNA-binding loop shifting down in the Apo structure but shifting upward in the 
NITD008- Helicase complex.  
ii) The P-Loop shifting away from the active site in the bound complex but being closed on 
the active site when no ligand was present.  
iii) The “325-338” loop shifting behind the active site and the “339-348” region being 
modified from a fluctuating310 Helix to a more stable α-Helix. 
 
6. The principal component analysis revealed a motional shift from a restricted structural motion of 
the unbounded form of the protein to a structural loop flexibility of the NITD008-NS3 Helicase 
system.  
            
The results presented herein have clearly contributed towards the molecular understanding of drug-
enzyme interactions and structural and conformational evolution upon ligand binding. It has also made it 
clear that inhibition of the non-structural protein of Zika virus at the replication stage of its life cycle will 
have great advantages to the clinical therapeutics of the virus. Furthermore, the computational techniques 
presented in this work has proven to be beneficial tools towards drug discovery and development. In 
addition, this research could contribute substantially to the design of novel inhibitor against the Zika 
virus, which will eventually bring about a cure to the notorious virus. Therefore, resulting to an improved 
quality of life of those affected by the virus, especially the pregnant women and children that were born 
with microcephally, Gullian-Barrè syndrome and other neurological diseases that are associated to the 
virus thereby, improving the health of the public at large. 
 
6.2. Recommendation and Future Studies 
The work presented in this thesis have identified lead compounds with good binding affinities. However, 
the lack of sufficient experimental data which could serve as a reference point for the presented models 
was a major challenge. Also, the lack of literatures with information on the structural conformations of 
the protein was also a challenge. These challenges serve as a source of motivation for this work.  
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As this is the first study reporting on drug-enzyme interactions and structural and conformational 
evolution upon ligand binding of Zika virus NS3 helicase, the following recommendations are noted to 
take this direction of research further: 
 A better free binding energy result can be achieved by using experimental data as a reference 
point. 
 Synthesis and prospective biological testing of these lead compounds is still required rationalizing 
their activity against Zika NS3 helicase. 
  Experimental assessments are needed to fully understand the loop shifts towards inhibiting the 
enzyme, and longer dynamic simulations may need to be run to validate the consistency of the loop 
flexibility. 
 Sophisticated computational approaches, such as, coarse grained molecular dynamics1, Substrate 
Envelope Analysis (SEA)
2
 and Quantitative Structure-Activity Relationships (QSAR)
3
, would 
provide a better understanding of the enzyme dynamics during the catalytic course. 
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Figure S1: 2D structures of potential ligand 
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Table S.1:  Grid box parameter for molecular docking. 
  
Table S.2: Binding energy result from docking selected potential Zika NS3 helicase inhibitors. 
 
APPENDICES 
107 
 
Appendix 2. Supplementary material for Chapter 5 
 
Delving into Zika Virus Structural Dynamics- A Closer look at NS3 
Helicase Loop flexibility and its Role in Drug Discovery 
Pritika Ramharack
A
, Sofiat Oguntade
A
 Mahmoud E. S. Soliman
A* 
 
A
Molecular Modeling and Drug Design Research Group, School of Health Sciences, University of 
KwaZulu-Natal, Westville Campus, Durban 4001, South Africa 
 
 
   
 
Supplementary Data 
 
 
 
 
 
 
APPENDICES 
108 
 
 
Figure S1: Potential Energy Fluctuations of the NITD008-NS3 Helicase System at varying temperatures 
during the 100ns simulation. The average temperature of the system was 300K and the average potential 
energy was -145774 kcal/mol.  
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Figure S2: Complex of NITD008-NS3 Helicase with a Docking score of -7.7 kcal/mol. MM/GBSA 
calculations yielded a result of -30.00 kcal/mol. The ligand shifted further out of the hydrophobic pocket 
after 150ns of the simulation. This may possibly be due to the ligand not interacting with the stabilizing 
residues of the P-loop.  
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Figure S3: Complex of NITD008-NS3 Helicase with a Docking score of -7.6 kcal/mol. MM/GBSA 
calculations yielded a result of -13.67 kcal/mol.The ligand docked out of the hydrophobic pocket and 
during the simulation, due to the lack of stabilizing interactions, the ligand moved further out of the active 
site and into the solvent.  
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Figure S4: Complex of NITD008-NS3 Helicase with a Docking score of -7.1 kcal/mol. MM/GBSA 
calculations yielded a result of -11.86 kcal/mol.This ligand showed a similar pose to that of the -7.6 
kcal/mol-docked pose, however, there was only one residue, Arg462, which showed stabilizing hydrogen 
bonds with the terminal oxygen located on the ribose group of NITD008.  
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Figure S5: Complex of NITD008- NS3 Helicase with a Docking score of -7.1 kcal/mol. MM/GBSA 
calculations yielded a result of -23.99 kcal/mol.This pose showed the same docking score as the above 
ligand, however, three residues: Arg462, Asn417, and Glu231, were involved in stabilizing hydrogen 
bonds. 
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Figure S6: MM/GBSA calculations yielded a result of -5.90 kcal/mol, which was lower than that of the 
docking score of 6.9 kcal/mol. This was due to the ligand binding out of the active site of the enzyme, 
thus leading to minimal intermolecular forces at the hydrophobic pocket.  
 
 
 
 
 
 
